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Cardiovascular diseases represent the leading cause of death in developed countries.
Modern surgical methods show poor efficiency in the substitution of small-diameter ar-
teries (< 6 mm). Due to the mismatch in mechanical properties between the native
artery and the substitute, the behavior of the vessel wall remains a major cause of
inefficient substitutions an unsolved complication in surgery since 1970. The potential
of decellularized scaffolds has raised major hope in several applications for regenerative
medicine. The purpose of this work was to obtain polylysine-enriched vascular substi-
tutes, derived from decellularized porcine femoral and carotid arteries. Polylysine was
selected as a matrix cross-linker, increasing the mechanical resistance of the scaffold
with respect to decellularized vessels, without altering the native biocompatibility and
haemocompatibility properties.
The biological characterization showed excellent biological performances, while me-
chanical tests displayed that the Young’s modulus of the polylysine-enriched matrix
was comparable to that of the native vessel. Burst pressure test demonstrated strength-
ening of the polylysine-enriched matrix, which resists at higher pressures with respect
to the native vessel. Mechanical analyses also show that polylysine-enriched vessels
presented minimal degradation compared to native.
Concerning haemocompatibility, the performed analyses show that polylysine-enri-
ched matrices increase coagulation time, with respect to commercial Dacron® vascular
substitutes. Based on these findings, polylysine-enriched decellularized vessels resulted
in a promising approach for vascular substitution.
In order to consider the industrial phase, a business plan (BP) and the pre-
engineering of the production reactor were developed in the present project. Is crucial
to consider the scale-up process of the project from the initial stages to increase the
chances of its success. In this way, the feasibility study will contemplate the viability
of the project from an economic point of view thus, the BP is the most important
document of the study. From an engineering point of view, the industrial production
reactor is the heart of the plant, so designing it from the outset will allow considering




Le malattie cardiovascolari rappresentano la principale causa di morte nei paesi
sviluppati. I moderni metodi chirurgici mostrano poca efficacia nella sostituzione di
arterie di piccolo calibro (< 6 mm), a causa della mancata corrispondenza delle pro-
prietà meccaniche tra le arterie native ed i sostituti vascolari. L’utilizzo dei materiali
decellularizzati ha costituito un’innovazione nella medicina rigenerativa. Lo scopo di
questo progetto è quello di ottenere sostituti vascolari arricchiti con polilisina, derivati
da arterie femorali e carotidi porcine decellularizzate. La polilisina è stata selezionata
come reticolante per la matrice, in modo da aumentare la resistenza meccanica dello
scaffold rispetto a quella del vaso decellularizzato, senza tuttavia alterarne le proprietà
naturali di biocompatibilità e di emocompatibilità.
La caratterizzazione biologica mostra un’eccellente biocompatibilità, ed i test mec-
canici dimostrano che il modulo di Young delle matrici arricchite con polilisina è simile
a quello dei vasi nativi. I test sulla burst pressure mostrano che la matrice arricchita
con polilisina resiste a più alte pressioni rispetto ai vasi nativi. I test di resistenza dina-
mica dimostrano anche che i vasi arricchiti con polilisina presentano una degradazione
minore rispetto a quella dei vasi nativi.
Riguardo l’emocompatibilità, le analisi svolte mostrano che le matrici arricchite con
polilisina aumentano il tempo di coagulazione rispetto ai sostituti vascolari in Dacron®
commercializzati. In base a queste scoperte, i vasi decellularizzati ed arricchiti con po-
lilisina risultano essere un promettente sostituto biologico per l’utilizzo in chirurgia
vascolare.
Con il fine di considerare nel progetto anche la fase di industrializzazione del
prodotto, sono stati sviluppati un business plan (BP) ed una pre-ingegneria del reattore
di produzione. Per incrementare le possibilità di successo del progetto è cruciale che
fin dall’inizio venga realizzato lo studio di fattibilità. Il BP è il documento più impor-
tante di tale studio, che infatti comprende la valutazione della sostenibilità economica
e finanziaria del progetto e ne stima la redditività. Da un punto di vista ingegneristico,
il reattore per la produzione industriale è il cuore dell’impianto, e la progettazione del
reattore fin dalle fasi iniziali permetterà di considerare i costi e gli eventuali esperimenti
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Arteries are a fundamental part of the human body since, not only do they transport
nutrients, but also oxygenated blood, metabolites, and waste products, they serve as
a conduit for hormonal communication between distant tissues and facilitate rapid
deployment of immune responses to distal sites within the body.
The aorta is the artery with a largest diameter (20 mm), which progressively divides
and decreases in diameter until reaching arteries with a diameter < 5 mm, they are
considered small. In turn, small arteries divide in arterioles (< 1 mm), which branch
further to become capillaries (< 100 µm), through which only single cells can pass.
Circulatory system is close due to capillaries joining together to form venules and the
diameter then increases in small veins, and then in larger veins which connect with
lungs and heart (Kottke-Marchant and Larsen 2006).
The structure of normal arteries is divided in three layers: the internal intima, the
middle media, and the external adventitia.
From the point of view of chemical composition, collagen is the most abundant pro-
tein in the elastic arterial (> 5mm diameter) extracellular matrix (ECM). Among the
different collagen types, collagen I and II represent the 30% and 60% of the total col-
lagen while collagen V, XII, and XIV represent the remaining 10% (Xu and Shi 2014).
The collagen role is retaining tensile strength, while the elastin fibers preserve the
elastic properties of the scaffold and GAGs provide it viscoelasticity (Wagenseil and
Mecham 2009). Other components present in the structure are elastin, fibronectin,
fibrillin, and laminin (Nair and Thottappillil 2015). Cell functions such as growth,
differentiation, and apoptosis are regulated by glycosaminoglycans (GAGs), proteo-
glycans, growth factors, cytokines, and matrix-degrading enzymes and their inhibitors
contained as well in the ECM (Ruoslahti and Engvall 1997).
Equally important, cell composition defines the mechanical properties and the func-
tion of the different layers. In this regard, cells in the intima and tunica media are
endothelial cells (ECs) and smooth muscle cells (SMCs), respectively. The most impor-
tant function of the endothelium, formed by the monolayer of ECs, is the prevention of
thrombosis but it is also responsible for the maintenance and alterations in the vascular
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tone, which control blood flow. The intima layer is delimited by the internal elastic
lamina formed by type IV collagen and laminin like ECM proteins (Pankajakshan and
Agrawal 2010).
Regardless of SMCs function, their circumferentially disposition along with collagen
and elastin fibers, provide mechanical support in the medial layer of the vessels. Due
to the SMCs contractile properties, they induce and produce not only the artery wall
expansion and contraction according with the blood flow cycle, but also they replenish
the ECM degraded fibers.
To contribute mechanical support, fibroblast, located primarily in the adventitia
layer, along with large bundles of collagen fibers, are responsible of the longitudinal
direction mechanical support (Lin et al. 2018). Adventitia layer function is to supply
nutrients to the cells in the blood vessel itself. For this purpose, it contains a small
arterioles and capillaries network which conform the vasa vasorum. Medial smooth
muscle cells contraction or relaxation is stimulated by a nerve also integrated in the
vasa vasorum layer. Adventitia thickness decreases progressively as the vessel diam-
eter decreases. Arterioles and capillaries lack an adventitia completely (Tucker and
Mahajan 2019). Figure 1 shows the different layers and cells compositions.
Figure 1: Arteries layers and its different cell population.
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1.1 General considerations. Outlook and clinical evaluation
of peripheral arterial disease. General overview
Non-communicable diseases (NCDs), which include cancers, cardiovascular diseases,
chronic respiratory diseases, and diabetes, are the leading cause of death in 70% of the
total world population (Bennett et al. 2018). Among the NCDs, cardiovascular diseases
are on top of the mortality ranking. Indeed, the World Health Organization (WHO) es-
timated 17,7 million people died in 2015 from cardiovascular diseases but the tendency
predicts a rise to 23 million worldwide by 2030 (Mathers and Loncar 2006; Rodrigues
et al. 2018). The commonest cardiovascular diseases are coronary heart disease (CHD),
cerebrovascular disease, peripheral arterial disease (PAD), and deep vein thrombosis.
All of them are mostly due to atherosclerosis, whose non-modifiable risk factors are
age, gender and genetic predisposition to hypercholesterolemia, hypertension, diabetes
and systemic inflammation. Concerning the modifiable risk factors cigarette-smoking,
diet rich in saturated fats and sedentary lifestyle can be identified (Settembrini et al.
2017).
Atherosclerotic cardiovascular disease may give rise to coronary artery disease
(CAD), myocardial infarction, stroke, and peripheral occlusive artery disease (PAOD).
Atherosclerosis is a multifactorial disorder of the arterial system, characterized by
vascular lipidic accumulation and calcification, with the development of lipid-laden de-
posits, or “plaques” in the vessel wall. Figure 2 shows the connections between the
diseases. This eventually leads to stenosis of the vascular lumen caused by lipid dis-
regulation and vascular inflammation that leads to endothelial injury (Kannan et al.
2005).
Figure 2: Overview of small caliber peripheral diseases.
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The normal blood flow is compromised through the artery as a consequence of the
stenosis and plaque formation, with subsequent thrombosis and this can lead to the
occlusion of the vessel and, depending on the artery location, it can result in an end
organ dysfunction.
Among the PAD, the occlusion of the lower extremities is predominant, and its
prevalence is estimated between 10% and 25% in < 55 years old population, but this
percentage increases up to 40% in > 80 years of age.
According with the American College of Cardiology/American Heart Association
Practice Guidelines, the PAOD can be categorized in asymptomatic, claudication, crit-
ical limb ischemia (CLI), and acute limb ischemia (ALI) depending on the stage of
plaque deposition in the lumen, which compromises the blood flow. Figure 3 repre-
sents the different stages of the vascular diseases and their treatment modalities.
Figure 3: Progressive stages of vascular disease and the corresponding surgical strate-
gies (Seifu et al. 2013).
In severe vascular trauma cases, laceration or transection of blood vessels can occur




1.2 Vascular replacements: clinical need for small diameter
replacements
Pharmacological and endovascular atherosclerosis therapies are improving their ef-
ficiency continuously, even so a surgical bypass of blood vessels on a lower extremity
remains the procedure of choice in several patients. This traditional treatment allows
the patient to keep his limb as an alternative to amputation. Cost-effective ratio of
this approach is also significantly better than other therapies (Olin et al. 2016).
Currently, the gold standard for the surgical treatment of diseased small-diameter
vessels are autologous arteries or veins due to their adequate physiological properties.
Saphenous veins (vena saphena magna) are the most commonly used autografts in
case of lower limb or peripheral bypass surgery. It has an easy access but due to the
mechanical mismatch, they often present aneurysm, intimal hyperplasia, and acceler-
ated atherosclerosis when exposed to high-pressure arterial sites (Akowuah et al. 2003;
Owens et al. 2009; Schmitto et al. 2010). Indeed, saphenous vein graft displays failure
rates of around 50% at 10 years (Harskamp et al. 2013; Klinkert et al. 2004). For this
reason, internal mammary arteries and radial arteries are also used because of their
superior patency (Athanasiou et al. 2011; Cho et al. 2006; Goldman et al. 2004; Masden
et al. 2012).
For example, in aorto-iliac bifurcation atherosclerosis, vessel substitution is the
best option if the occlusion is severe but, in 15% of patients, the saphenous vein is not
available due to its prior use for coronary artery bypass surgery (Desai et al. 2004).
On the other side, autologous vessels present a limited availability, may be of poor
quality, and their extraction causes donor site morbidity (Chew et al. 2002; Conte
2013; Klinkert et al. 2004; Taylor et al. 1987).
Mismatch in compliance and elasticity between the autologous graft and the na-
tive vessel often leads to re-occlusion, due to atherosclerotic progression and cellular
infiltration. Furthermore, previous phlebitis, vessel removal, varicosities, hypoplasia,
or anatomical unsuitability are presented in almost 30–40% of the patients, this causes
the absence of a viable saphenous vein (Kannan et al. 2005).
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Table 1: Biological vascular grafts in clinical use (Boccafoschi et al. 2017b).
An alternative approach proposes to use the human umbilical vein as vascular graft
for peripheral substitutions, it is named Dardik Biograft. Currently it is the best option
when the saphenous vein is not available. In the graft preparation, the umbilical vein
is treated with dialdehyde starch or glutaraldehyde and is reinforced with an outer
polyester fiber mesh. In this way, the native basement membrane in the luminal side
of the vessel guarantees the thromboresistance. Nevertheless, Dardik Biograft presents
complications such as infections, thrombosis and aneurysm, usually due to the surgical
method (Eskandari 2015).
During the last 50 years regenerative medicine tried to obtain a satisfactory alterna-
tive in that case. Early 1960s, fresh or cryopreserved homografts (i.e., human allografts
from cadaver donors) was abandoned owing to difficulties in preserving them, late graft
deterioration and aneurysm formation. As an alternative, synthetic prosthesis were in-
troduced due to the anticipated availability. Currently homografts are not routinely
used, but they have been reintroduced to treat aortic prosthetic graft infection, lower
extremity primary revascularization, and simultaneous or sequential revascularization
surgery in solid organ transplant recipients (Boccafoschi et al. 2017b).
Currently, the available alternatives to autologous vessel are different according to
the vessel diameter (Table 2). Arteries with a diameter greater than 8 mm are consid-
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ered large-caliber arteries. In this case prosthesis made with synthetic material obtain
a good result from the critical thrombogenicity point of view. Dacron® (INVISTA
Technologies S.r.l., Saint Gallen, Switzerland) prosthesis is the commercial product in
these cases (Figure 4).
Figure 4: Dacron® straight prosthesis implanted in the abdominal aorta.
There is not a clear preference between natural and synthetic grafts in medium
caliber replacements, diameter between 6 and 8 mm, typically carotid and femoral
arteries. The results are controversial, but the solution exists.
The alternative to autologous transplant for small-caliber vessels (< 6 mm), such
as coronary arteries (heart), infrainguinal arteries (below the inguinal ligament), and
particularly in low-flow infrageniculate arteries (below the knee joint), is not currently
up to standard and the statistics prove that 5-years patency falls to 15%–30%. In this





































Table 2: Vascular substitutes in clinical use according to the body region (Boccafoschi
et al. 2017b).
As reported by Couet et al. (2007), vascular tissue engineering “aims to apply
the principles of engineering and life sciences towards the development of a vascular
construction that demonstrates biological and mechanical properties as close as possible
to those of a native vessel”.
Tissue engineering offers two main alternatives to autologous vessel, prosthesis made
with natural or synthetic materials. Independently of the material origin, the prosthesis
must achieve multiple requirements. First of all, the material should be biocompatible.
That is to say, it must satisfy characteristics such as: nontoxicity, nonimmunogenicity,
resistance to in vivo thrombosis, ability to withstand infection, complete incorporation
into the host tissue with satisfactory graft healing and ability to grow when placed
in children, maintenance of functional endothelium and in general functional vascu-
lar cells. In particular, in vascular substitutions, dysfunctional endothelium becomes
adhesive to inflammatory cells, exposes thrombogenic surfaces and, thus, promotes
inflammation, atherosclerosis and thromboembolism.
Secondly, a vascular graft should possess adequate mechanical properties related
to the anatomical replacement needed, this means that the vascular substitute needs
to possess compliance and burst pressure similar to that of native vessels in order to
withstand long-term hemodynamic stresses. These characteristics guarantee no modi-
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fications in the hemodynamic environment, therefore, avoiding the induction of inflam-
matory and clotting response which may lead to lumen stenosis after the implant. In
the peripheral regions, the vascular substitute may also resist to kink and compression
forces without undergoing any structural modification. Good operative suturability
and simplicity of surgical handling are essential qualities for a suitable surgical device
(Meyer et al. 2009).
Regarding the prosthesis processability, low manufacturing cost, readily availabil-
ity with a large variety of lengths and diameters, serializability and easy storage re-
quirements are mandatory to obtain a good industrial product. This aspects will be
considered in the industrialization chapter in order to obtain an optimal technology
transfer process (Catto et al. 2014).
1.3 Current biological options: perspectives in vascular tissue
engineering and peripheral substitutions
Scaffold biomaterials are classified into two broad categories based on their origin
which can be natural and/or synthetic (Figure 5).
Synthetic polymers are manufactured, and they allow stricter control over physical
and mechanical properties in order to mimic the natural matrix by chemically tailoring
polymers. However, they lack the natural capacity of bidirectional communication with
cells. In order to minimize this restriction, soft, porous materials such as hydrogels
can incorporate cells, adhesive ligands, and proteolytically degradable peptides. The
standard production method and the easy sterilization phase are the reasons for the
use of synthetic polymeric biomaterials in tissue engineering.
By contrast, natural biomaterials are derived from both plant and animal sources
and intrinsically contain biological cues, such as growth factors, or sites that pro-
mote cell adhesion and/or degradation. Most natural materials used as biologically
derived matrices are composed by proteins and polysaccharides. Collagen, gelatin,
fibrin and silk are widely used in tissue engineering applications due to the intrinsic
non-immunogenic properties and the ability to tune the mechanical properties by tai-
loring the amount of crosslinking within the gel. However, their mechanical properties
18
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performance are not acceptable. In order to fix this main problem, cross-linking agents
and copolymers such as collagen, fibrinogen, chitosan, alginate or hyaluronic acid with
poly lactic-co-glycolic acid are used to improve the mechanical strength and minimize
the degradation predisposition. Another approach is nanoscale fibers electrospinning,
in this context, fibrin is usually used and it can form scaffolds exhibiting high structural
integrity while retaining biological activity (Taylor et al. 2018).
Figure 5: Scheme of origin material of arterial scaffold. Modified from Tara et al.
(2014).
In vitro vascular graft recellularization using autologous patient cells is a promising
approach in order to avoid thrombosis and a host immunogenic response, but it presents
a lot of problems in terms of the subsequent implementation. One of these problems
is given by the time necessary to obtain the needed cells from the patient. Another
issue is the assuring of the isolated cell line from the patient remains stable during its
in vitro amplification time. All this has an important impact on the cost effectiveness




Synthetic scaffolds are composed of polymers whose properties can be tailored to
the target tissue, that are easy to process, have high reproducibility between batches
and, compared to natural polymers can be produced in large amounts under asepsis
conditions. By contrast, they exhibit some negative features like low biocompatibility
and cell adhesion, fistula formation, gradual degradation into byproducts that may be
toxic and chronic inflammation that results in serious dysfunctional and mechanical
degradation of the transplant which may be, inter alia, the reason of clinical failure.
The two main categories of synthetic materials are non-biodegradable and biodegrad-
able.
Non degradable
Initial vascular prosthesis utilized non-degradable polymers like polyethylene tereph-
thalate (PET, Dacron®) and expanded-polytetrafluoroethylene or Teflon (ePTFE,
Gortex®) and they still dominates the market for large and medium diameter vessel
due to the fact that they require grafts greater than 6 mm in diameter in a high-flow,
low-resistance circulation (Tara et al. 2014).
Electronegative luminal surface and porosity properties allow a 5 years patency of
91% in the ePTFE case. Also, flexibility, elasticity and kinking resistance of PET con-
fers an excellent performance in terms of platelet adhesion and leukocyte aggregation
when compared with ePTFE. Unfortunately, for small-diameter vessels (< 6mm) its
use is limited due to poor patency rates related to thrombosis and stenosis (Nair and
Thottappillil 2015).
Despite the low thrombogenicity and exceptional physical and mechanical proper-
ties, the first generation of polyurethanes (PU) was unstable and failed in clinical trials
but, the second generation, materials based on PU combined with different materials,
such as urea, fibronectin, collagen, and elastin obtained promising results in terms of
endothelialization and platelet adhesion when compared to the unmodified PU scaf-
folds. On the contrary, the involvement of toxic precursors like toluene diisocyanates
in PU synthesis is the major limitation of this synthetic polymer in the biomedical field
(Pankajakshan and Agrawal 2010).
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PET and ePTFE prosthesis used for small caliber vessels fail due to the insuffi-
cient functional endothelium regeneration and the differences between the mechanical
properties of tissue-engineered vascular graft (TEVG) and natural blood vessels (Catto
et al. 2014).
Degradable
Biodegradable polymers can be used as provisional structures for blood vessels
before the ingrowing tissue replaces them. Their degradation produces chemical sub
products of smaller molecular weight when metabolism, via hydrolytic cleavage at the
ester bond, occurs. These products may alter the local cellular environment and could
affect the cell functions. After this process, the materials suffer a loss of mechanical
properties followed by a reduction of mass and/or volume, and the speed depends on
different parameters such as the initial molecular weight, the exposed surface area and
the crystallinity (Tara et al. 2014).
One of the most used biodegradable polymers in tissue engineering is poly glycolic
acid (PGA). It is a semicrystalline thermoplastic of aliphatic polyester and it is pro-
duced by the ring-opening polymerization of glycolide. It completely degrades in vivo
within 6 months and is a material approved for human clinical use (Couet et al. 2007;
Pankajakshan and Agrawal 2010).
Typically, PGA is combined with polylactic acid (PLA) in different ratios to syn-
thetize it, poly lactic-co-glycolic acid (PLGAs). PLA is a thermoplastic aliphatic
polyester synthesized by ring-opening polymerization of lactic acid. PLA degrades
slower than PGA and usually its degradation rate is controlled by mixing it with PGA.
PLA L-chiral molecule poly-L-lactide (PLLA) can take months or even years to degra-
date, because it is more hydrophobic, and its biocompatibility is good (Chen et al.
2002).
Although PGA presents a good biocompatibility, in vitro studies suggest that its
breakdown products may induce inflammatory response (Higgins et al. 2003). In
addition, low differentiation ratio and cell proliferation support the fact that, PGA
doesn’t represents an optimal vascular scaffold for tissue engineering (Pankajakshan
and Agrawal 2010).
Due to their hydrophobic properties, poly ǫ-caprolactone (PCL) and PLA present
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a successful option for different clinical applications. PCL is a semicrystalline aliphatic
polyester and among other advantages it presents a very slow degradation rate produc-
ing degradation products that don’t interfere with cell proliferation, easy fabrication,
optimum porosity and viscoelastic properties.
As a consequence, they are commonly used like arterial scaffold materials. Since,
PCL and PLA used alone cannot reach the mechanical performances for small artery
pressure and high flow conditions, they are used combined with additional synthetic
polymers to create copolymers such as poly(llactide-co-ǫ-caprolactone) (PLCL), with
fine tuning of mechanical properties and degradation rates by controlling the compo-
sition ratio and molecular weights. Even though the mechanical scaffold properties
feasibility of the in vivo studies are demonstrated (Tara et al. 2014) these studies also
show a delayed tissue remodeling. Hence, mechanical properties of biodegradable scaf-
folds are important for their clinical success, Table 3 shows different parameters in













PGA 230 36 890 8,4 30 2–3 weeks
PLA 170 56 900 8,5 25 6–12 months
PCL 60 –60 50 0,3 70 12 weeks
PLCL (LA/CL = 75/25) 140 22 500 4,8 70 8–10 weeks
PLCL (LA/CL = 50/50) 105 –17 12 0,9 600 4–6 weeks
Table 3: Biodegradable polymers for tissue engineered vascular grafts (Tara et al.
2014). Tm, melting temperature; Tg, glass-forming temperature.
Focusing on improving PLA cell affinity and haemocompatibility, many authors
synthetized synthetic copolymers such as poly lactideco-b-malic acid (PLMA) with
minimum platelets attraction and enhanced cell proliferation (Wang et al. 2009) or in
combination with biological materials like gelatin, elastin, collagen I (Li et al. 2006;
Stitzel et al. 2006).
Poly glycerol sebacate (PGS) is a bioelastomer created specifically to fulfill the
requirements of a dynamic mechanical environment such as the cardiovascular system.
It degrades in vivo by hydrolysis in 2 months and is Food and Drug Administration
(FDA) approved for medical applications (Catto et al. 2014).
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These poor mechanics, combined with the lack of endothelialization and the throm-
bogenic nature of the synthetic surface, leading to thrombosis and luminal narrowing,
due to intimal hyperplasia, are reflected in their poor long-term patency (Kannan et al.
2005; Lemson et al. 2000).
1.3.2 Scaffolds from natural polymeric materials for vascular tissue engi-
neering
Collagen
Collagen is the main ECM protein in the body and its function is to provide me-
chanical support to contrast action forces and, at the same time the collagen type and
fiber orientation define the different kind of cells and their disposition in the tissue.
Until now 29 types of collagen were individuated, but collagen I and II represent
30% and 60%, respectively, of vascular wall composition. Collagen I primary structure
is formed by 3α helix and each chain has about 1.014 amino acids. The amino acids
sequence along the entire chain is composed by the tripeptide sequence of -(Gly-X-
Y-)n-, where glycine (Gly) constitutes about 30% of the total amino acid content in
collagen and generally, X is a proline and Y is an hydroxyproline (Liu et al. 2019).
Collagen presents low antigenicity, low inflammatory response, biocompatibility,
biodegradability, and excellent biological properties (Couet et al. 2007; Marelli et al.
2012; Pankajakshan and Agrawal 2010). As a result, it was the first material used in
attempt to develop a blood vessel scaffold using a biological material.
In 1986, Weinberg and Bell created a blood vessel cocultured of ECs and SMC
cells in a collagen tube. Unfortunately, this scaffold had poor mechanical strength and
years after a Dacron® support was integrated into the structure, between the media
and adventitial layers, to reinforce the vessel. Regrettably, synthetic material caused
complications, such as immune rejection and compliance mismatch (Seifu et al. 2013)
and the conduit were unable to reach adequate burst strengths for in vivo applications
(Pankajakshan and Agrawal 2010).
Different techniques that utilize collagen as a scaffold were used over the years. No-
tably, bioreactors were used to endothelialize collagen constructs and stimulate the rate
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of matrix remodeling through pulsatile circumferential stretch action on SMCs metallo-
proteinase-2 production. Combination of collagen with other synthetic polymers, for
example poly-(glycolic acid), poly-(lactic acid) and poly-(L-lactide-co-ǫ-caprolactone)
(Boccafoschi et al. 2017a), and use of cross linking agents, like ultraviolet radiation
(Achilli et al. 2010; Haisch et al. 2000; Rajan et al. 2008), attempted to increase the
mechanical performances.
However, the reason why collagen is not the best option to use in the matrix is
that the degradation product of collagen results in the production of amino acids that
have thrombogenic potential and activate the coagulation cascade. In addition, high
cost of pure collagen also curtails its use as a cost effective approach to vascular graft
construction (Nair and Thottappillil 2015).
Elastin
Elastin is a protein that can be found in some mammalian tissues and it is produced
until puberty. In particular, it plays an important role in the blood vessel ECM because
it provides enough elasticity to ensure the correct blood flow (Couet et al. 2007). This
protein confers elastic recoil, resilience, and durability to the arterial wall and the
reason can be found in its microstructure.
Elastin is made of its soluble precursor tropoelastin, this results in an insoluble
polymer. The elastic fiber is composed of amorphous elastin and microfibrils which act
as a scaffold on which elastin is deposited. An important property of tropoelastin and
elastin-like peptides is their potential to self-assemble under physiological conditions.
As collagen, cross-linking fibers are mediated by lysil-oxidase and take to sequential
reactions leading to the functional and insoluble form of elastin (van Eldijk et al. 2012).
Collagen contains 1–4 cross links per unit, whereas elastin has 15–20 cross-links which
cause the different mechanical behavior. Indeed, these characteristics are palpable
when the compliance is measured, due to the fact that elastin stores elastic energy and
high strain to ensure smooth blood flow (Nair and Thottappillil 2015).
The addition of elastin to create a scaffold has been proved very useful for inducing
cell activity, elastic recoil to collagen fibers in the case of strain, and at the same time
reducing the rigidity in collagen-elastin for vascular scaffolds application (Boland et al.
2004). Recent works study different techniques to add elastin to scaffolds, collecting
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data about the resulting mechanical properties (Williams et al. 2009; Buijtenhuijs et al.
2004), or the process of electrospinning which makes it able to control the composition,
the structure, and the mechanical properties of biomaterials.
In conclusion elastin, considered as a biomaterial, has a very high potential for
VTE due to its favorable properties such as resistance to degradation, easy purification,
and low thrombogenic potential (Hinds et al. 2006), but it is still limited due to the
problems represented by the task of mixing, solubilizing, and processing elastin with
other materials to obtain a scaffold with a well-organized microstructure (Couet et al.
2007). The main reason why it is not used as often as other natural protein-based
material, is because during the purification process, contaminations often take place
which can then lead to immune responses by the body.
Furthermore elastin has a tendency to calcify (Bobryshev 2005; Khavandgar et al.
2014-02; Pai et al. 2011-02). In recent years more successful elastin purification methods
have been developed (Daamen et al. 2001), however since elastin is highly insoluble, its
soluble forms are often used, like tropoelastin, alpha-elastin, elastin like polypeptides
(ELPS) and a type of genetic-recombined elastin (ELRs).
Fibrin
Fibrin is a natural fibrillar protein which can form three-dimensional structures. It
is naturally involved in wound healing and tissue repair due to the fibrin clots provid-
ing structural scaffolding for adhesion, proliferation, and migration of cells involved in
the repairing process. The goal of using fibrinogen precursors of polymeric fibrin iso-
lated from the patient’s own blood to build the scaffold is to eliminate immunological
concerns of human or cross-species donor incompatibility. Cells which grow on fibrin
scaffolds seem to produce more collagen and elastin than cells entrapped in a collagen
gel but this is not enough to increase the weak mechanical strength. To increase the
elastin fibers and collagen amount from SMCs, the initial fibrin scaffold was enriched
with TGF-b and insulin. Also, incorporation of angiogenic and platelet growth fac-
tors can improve the synthesis of elastin and collagen by the vascular cells. In order
to improve the cell adhesion, specific adhesion receptors can be cross-linked into the
fibrin matrix. Moreover, several studies support the incorporation of specific biochem-
ical factors, like fibroblast growth factor 1 and heparin, into fibrin matrices. There
25
Introduction
are a variety of other ECM proteins (fibronectin, hyaluronan, and laminin) that upon
incorporation to fibrin may further enhance the properties and functions of engineered
tissues. However, fibrin localization poses a problem of initiation of the coagulation
cascade and the degradation profile of fibrin requires a detailed investigation.
Fibrin is a protein particularly involved in the natural repairing process of tissues
and in the coagulation cascade. Fibrinogen is the inactive form of fibrin and when
activated it plays a key role in wounded tissue regeneration by forming an extensive
fiber network. In this context, fibrillar gel composed of fibrin clots provides support
forming a scaffold which is involved in the final healing process.
Fibrinogen can be obtained from blood and it can be used as an autologous source
for the scaffold, mitigating or eliminating the risk of immunological incompatibility
(Catto et al. 2014). These materials are considered an alternative solution to collagen
due to the fact that they are easily obtained from the patient’s blood (Seifu et al. 2013).
Fibrin based hydrogels are commonly used in cardiac tissue engineering, however
the main obstacle is their low mechanical strength. Nevertheless, some studies report
that cells grown into a fibrin gel produce more collagen and elastin than cells seeded
into a collagen gel (Grassl et al. 2002). For example, Seifu et al. (2013) shows that
cell-seeded fibrin gels implanted in a vein of chronically heparinized lambs improved
the mechanical properties and the elasticity of the graft after 12 weeks.
Several studies probed the techniques for improving the healing process. Among
these studies we can remark: incorporation of vascular endothelial growth factor (VEGF)
in fibrin that promotes the endothelial proliferation and maturation (Santhosh Kumar
and Krishnan 2002) and binds specifically and saturable to both fibrinogen and fibrin
(Sahni and Francis 2000); the incorporation of specific factors like fibroblast growth
factor 1 and heparin in fibrin (Zarge et al. 1997); and the incorporation of fibrin into
biodegradable polymers that can be used to combine the biological properties of fibrin
with the mechanical properties of the polymer to define an approach to improve the
mechanical strength of the scaffold for vascular tissue engineering (Pankajakshan and
Agrawal 2010).
Chitosan
Chitosan is a linear polysaccharide composed of b-(1–4)-linked D-glucosamine with
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randomly dispersed N-acetyl-D-glycosamine groups, obtained by partially deacetylat-
ing chitin, the primary structure of arthropods exoskeletons. Structurally chitosan
is similar to the glycosaminoglycans contained in the ECM. Physical and mechanical
properties are directly correlated with the molecular weight of the polymer and the
degree of deacetylation.
The advantages of using chitosan in tissue engineering are: the antibacterial prop-
erties, it is easy to sterilize, it contains nitrogen, it has a low cost, it is bioactive,
biocompatible and its degradability can be controlled by changing the level of deacety-
lation (Huang et al. 2005). This type of material is easily affected by parameters such
as pH and temperature. Among its disadvantages we find its poor mechanical prop-
erties, however this problem can be overcome by crosslinking with chemical materials
(Vieira et al. 2002) or with gelatin (Nair and Thottappillil 2015).
In tissue engineering chitosan is an advantageous biomaterial choice, due to its
low cost, ease of production, antimicrobial activity, biocompatibility, biodegradability,
and bioactivity (Huang et al. 2005). Chitosans antibacterial properties and its stim-
ulatory action on leukocytes gives it an enormous potential as a natural polymer for
wound-healing applications (Hamedi et al. 2018). On the other hand, it is necessary
consider the poor mechanical properties, which are usually improved by blending it
with synthetic polymers and even with gelatin (Nair and Thottappillil 2015).
Chitosan was studied as a vascular scaffold in combination with gelatin by Zhang
et al. (2006) who fabricated a two layers tubular chitosan and gelatin scaffold. In order
to improve the endothelial cells (ECs) and smooth muscle cells (SMCs) spreading and
proliferation, chitosan was modified with dextran sulphate with satisfactory results in
vitro and in vivo (Chupa et al. 2000). To reduce the possibility of clot formation in the
vessel, Madihally and Matthew (1999) designed a family of chitosan scaffolds which
include heparin-modified porous tubes.
Glycosaminoglycans
Glycosaminoglycans (GAGs) are long unbranched chains composed of disaccharide
units containing carboxylic and/or sulphate ester groups. These functional groups
bridge and link collagen to form the ECM network.
An example of GAG is hyaluronic acid (HA), present in the mammalian connec-
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tive tissue where it acts as a lubricant. HA is an anionic non-sulphated GAG that
consists of glucuronic acid and N-acetyl glucosamine (Couet et al. 2007). HA has
some remarkable properties such as hydrophilia, non-adhesiveness, biodegradability
(Couet et al. 2007; Huang et al. 2004), and the ability of being completely resorbable
through multiple metabolic pathways (Bencherif et al. 2008). Another advantage of
HA is that its production is easy and controllable in a large scale through microbial
fermentation (Pankajakshan and Agrawal 2010), avoiding the risk of animal-derived
pathogens. Moreover, HA can bind large amounts of water to form hydrogen bonds
with the solvent.
There are studies that evidence that HA is involved in angiogenesis, ECM organiza-
tion, wound healing, inflammation, and other biological processes (Pankajakshan and
Agrawal 2010). The studies on graft based esterified HA show a lower axial strength
and higher stiffness compared to normal porcine arteries (Remuzzi et al. 2004). Im-
provements on the creation of an endothelial monolayer when compressed are achieved
through Hyaff-II, a biomaterial obtained from the total esterification of hyaluronan
with benzyl alcohol (Pankajakshan and Agrawal 2010). Porcine model implanted with
Hyaff-II showed graft occlusion at the end of 3 months, however the graft almost com-
pletely degraded while the formation of neo-tissue was complete with endothelium,
organized collagen, and elastin (Zavan et al. 2008). This scaffold allows neoangiogene-
sis and endothelialisation of the luminal surface, it supports elastin synthesis without
chemical and cellular preconditioning in vitro, for these reasons it is considered a very
promising solution (Pankajakshan and Agrawal 2010). HA derivatives are used suc-
cessfully as scaffold materials for chondrocyte growth (Prestwich 2011), for bone and
skin regeneration, for treating vascular diseases due to the biocompatibility and anti-
inflammatory properties (Burdick and Prestwich 2011).
Silk Fibroin
Silk fibroin is a protein produced by silkworms, spiders and scorpions, even though
it is mainly obtained from Bombyx mori silkworm. Its main amino acid composition
is 43% glycine, 30% alanine, and 12% serine (Vepari and Kaplan 2007).
It is possible to obtain dissolved silk fibroin by using different kinds of solvents
like lithium bromide, formic acid, ionic liquids, and the ternary solvent system CaCl2/
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ethanol/ water. The previous necessary step consists on removing sericin, an antibac-
terial and UV-resistant protein which glues the silk fibers, using a degumming process
via dilute sodium carbonate solution or urea, citric acid, and sodium oleate (Kim et al.
2017). In order to stabilize the film produced with fibrin, silk I and II are combined.
Silk I is water soluble, whereas silk II has an antiparallel beta-sheet conformation and
is insoluble. Young’s modulus, strain and tensile strength are improved when silk I is
converted into crystalline silk II through an annealing process (Han et al. 2014).
Because of its excellent mechanical properties, low adverse immune reaction, min-
imal thrombogenicity, and compatible degradation rates it is employed in vascular
tissue engineering (Nair and Thottappillil 2015). Furthermore, it is compatible with a
number of manufacturing process, such as electrospinning or gel spun.
Nakazawa et al. performed an in vivo study using a rat model, it shows a patency
rate of 85% after 12 months, with no thrombosis or aneurysm observed. It was also
suggested that the mechanical properties of these scaffolds could be improved to better
emulate those of the native vasculature by using fiber alignment techniques during the
manufacturing processes (Nakazawa et al. 2011).
Three-dimensional (3D) printing technology employs silk hydrogels with different
techniques such as extrusion, lithography and recently digital light process using a
grafting methacrylate (Kim et al. 2018). Silk is also combined with other biopolymers,
such as gelatin and alginate, to obtain the adequate rheological characteristics for the
bioink (Wang et al. 2019).
Gelatin
Gelatin is a natural and low-cost vascular polymer whose properties, such as mini-
mal immunogenicity and appreciable degradability, make it one of the best options for
tissue engineering. This polymer is obtained through denaturing the triple helical con-
formation of collagen; there are two types of gelatin derived from 2 different treatments:
gelatin A processed by acids (pH 1–3) and gelatin B processed with alkaline solutions,
type A being the most preferable for scaffold building. Gelatin has also been used as
a coating agent to enhance cell attachment in vascular tissue regeneration techniques
(Nair and Thottappillil 2015).
Gelatin presents gel forming, thickening, emulsifying and foaming proprieties. The
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mechanical ones depend on the supramolecular structure (Kozlov and Burdygina 1983).
Synthetization of anionic or cationic gelatin is based on extraction conditions and
fundamentally for filling molecules through electrostatic interaction. Since gelatins
stability at high temperatures and wide range of pH allows synthetic polymers to be
grafted on gelatin backbone. Methods are “grafting from”, polymerisation on the
functional surface of the substrate, “grafting to”, grafting end functionalized polymer
to the substrate, or “grafting through” (Sadeghi and Heidari 2011).
Methacryloyl group-grafted gelatin, also known as gelatin methacrylate (GelMA)
has been used for 3D printing in microfabricated blood vessel. Gelatin electrospun
fibers loaded with antibiotic drugs (ciprofloxcacine) have a strong antibacterial activity
but in this case gelatin has to be reinforced with materials such as graphene oxide and
boron nitride to improve poor mechanical proprieties. (Bakhsheshi-Rad et al. 2017;
Nagarajan et al. 2016a,b, 2017).
Using electrospinning processes to generate tubular scaffolds allows to obtain a sim-
ilar morphology to the native ECM structure, gelatin copolymer behaved as a natural
cell responsive surface under mechanical stimulation (Thomas and Nair 2012).
Panzavolta et al. (2011) obtained electrospun gelatin nanofibers cross-linked with
genipin, a low-toxicity agent, which reduces the extensibility of the electrospun mats,
producing appreciable improvements in elastic modulus and breaking stress. Long-
term studies on cross-linked electrospun gelatin are still under study to confirm its
efficacy as a scaffold material for blood vessel tissue engineering.
Alginate
Alginate is a polysaccharide component of brown algae cell walls and some bacteria
capsules (Draget et al. 2005). Its structure is based on two different monomers: b-
D-mannuronate (M) and a-L-guluronate (G) organized into blocks. Since G-blocks
form ionic bridges, alginates mechanical properties are related with the number and
disposition of these blocks (Draget and Taylor 2011). From the biological point of view
for medical applications alginate presents nontoxic and noninflammatory properties,
in vivo degradation does not occur, however cell adhesion is poor and mechanical
characteristics are insufficient. Alginate applications were explored in different tissues




Polyhydroxyalkanoate (PHA) and copolymers are polyesters produced by differ-
ent bacteria which synthetize carbonic chains with different longitudes depending on
the carbon nutrients limitation. Mechanical properties and degradation rates can be
modified according to the longitude chain of the molecule (Williams et al. 1999).
PHAs remarkable characteristics are its biocompatibility, thermoplasticity, and/or
elastomericity, which allows ease of handling during suturing (Valappil et al. 2006).
Although PHA vascular grafts sustain cell attachment and proliferation, in vivo stud-
ies often present an acute immune response. Lipopolysaccharides produced by gram-
negative bacteria when PHAs are synthetized appear to be the origin of the problem.
Several studies confirm this theory for vascular conduits made with PHAs. For
example, a hybrid tubular scaffold PHA-PGA was implanted using an ovine model
and, after 5 months the mechanical properties were similar to the ones of native tis-
sue (Shum-Tim et al. 1999). Another study uses a blood vessel scaffold engineered
using PGA coated with poly(4-hydroxybutyrate), combined with fibrin gel and seeded
with human myofibroblasts. In vitro tests under dynamic strain conditions showed
burst pressure results comparable with mammary artery physiological conditions (300
mmHg) after 28 days (Stekelenburg et al. 2009).
1.3.3 Hybrid scaffolds from synthetic and natural polymers
Synthetic and natural polymers can be combined to obtain a hybrid scaffold, so the
excellent biological performance of natural polymers with the satisfactory mechanical
properties of synthetic materials are combined. With this objective, Table 4 summa-
rizes the relevant studies on TEVGs made using hybrid scaffolds.
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SEM and fluorescence microscope
(3 days): HUVECs attached and
proliferated; platelet attachment:
reduced, compared to ePTFE and
PCL
Model: rabbit (1 month); mainte-
nance of physical integrity; no ev-
idence of dilatation, anastomotic
dehiscence, or seroma; mechanical
properties of implanted grafs re-
mained similar to controls
Wise et al.
(2011)
PGA + PLLA +
collagen type I
Cell culture with NIH/3T3 or HU-
VEC (3 days); SEM analysis:
higher cell number and better ad-
hesion for grafs with collagen
Model: dog (12 months); acellular
grafs; 100% patency, no thrombo-
sis or aneurysm; excellent tissue re-
generation: complete endothelial-
ization, SMCs, elastin, and colla-
gen fibers; PGA fibers completely
absorbed at 2 months, PLLA fibers




Blend of PCL +
collagen type I
ECs and SMCs from bovine
carotid artery; cytotoxicity via di-
rect contact (7 days—MTS assay):
no differences in cell viability com-
pared to TCPs; cytocompatibil-
ity (7 days—MTS assay): EC and
SMC adhesion and proliferation;
cell culture on tubular grafs (48
h—SEM and histological analysis):
SMCs formed multiple cell layers
on the outer region, ECs formed a




Blend of PCL +
collagen type I
ECs derived from endothelial pro-
genitor cells isolated from live
sheep; SMCs isolated from sheep
artery explants; dynamic culture
using a pulsatile bioreactor under
physiologic conditions (9 days);
SEM + histological analysis: ECs
formed a confluent layer on the in-
ner lumen, SMCs assumed a mul-
tilayered confguration on the exte-
rior
Platelet adhesion in a live sheep
model for 15 min: no adhesion for
seeded grafs, abundant adhesion
for unseeded grafs; model: rab-
bit (1 month); acellular grafs; no
aneurysmal degeneration; major-
ity of the grafs remained patent at







HCAECs rotationally seeded in
the bioreactor for 4 h + static cul-
ture (10 days—SEM and histologi-
cal analysis): HCAECs evenly dis-
tributed and well spread on the lu-
men
Model: rabbit (7 weeks); acellu-
lar grafs without collagen coating;
no blood leaking; graf structure in-
tegrity and patency; foreign body




ECs, SMCs, and fibroblasts iso-
lated from ovine carotid arteries;
ECs seeding in the inner layer us-
ing a rotating chamber; dynamic
culture in a bioreactor under phys-
iological pressure conditions for
21–28 days; histological analysis: a
dense, homogenous distribution of
cells throughout the scaffold thick-
ness, extensive collagen formation,
and no evidence of calcification
Model: sheep (6 months); D ∼
6 mm; cellular grafs (dynamic
culture for 21–28 days); at 3
months 1 graft with a significant
stenosis; other grafs: completely
patent, no thrombus formation
and aneurysm, infection, or cal-
cification; remodeling: confluent
endothelium, collagen and other
ECM components, and elastin (not
assembled in cohesive sheets); fib-
rin completely degraded after 1
month, sparse PLDLA material re-
mained at 6 months
Koch et al.
(2010)
Table 4: TEVGs made using hybrid scaffolds (Catto et al. 2014).
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1.4 Decellularized vascular substitutes
The goal of tissue or organ decellularization is to mimic the native tissue and provide
a proper environment for cells, through the removal of cells, while preserving the micro
and macro architecture of ECM and the niche for cells.
In order to obtain an optimal decellularized matrix, many factors must be con-
sidered, which include: the tissue source (the species from which the material has
been obtained), the preparation procedures and the efficacy of decellularization. In
addition, other factors, such as the use of chemical cross-linking agents or the final
sterilization, should be under control because they may also affect the structure of the
ECM (Kawecki et al. 2018).
Biological scaffolds are typically allogeneic or xenogeneic in origin, for this reason
a maximal decellularization is desirable in order to minimize immunologically induced
inflammation (Crapo et al. 2011).
Specific tissue and organ characteristics, such as cell density, matrix density, geo-
metric, tissue thickness and shape, should be considered to process it with the optimal
decellularizing method. To preserve the matrix’s micro/nano-structure, composition
and biological activity properties, the decellularization method should be selected ra-
tionally and should be scientifically justified for each kind of matrix or organ (Kawecki
et al. 2018). The critical point is not only to use the optimal physical force exposure,
but also the choice of non-physiologic chemical and biologic agents such as detergents
and enzymes. These aspects will be analyzed below. In the specific case of blood ves-
sels, usually the process consists of mechanical shaking, chemical surfactant treatment
and enzymatic digestion. The validation and consolidation of the method effectivity
must be guaranteed. The right choice of an optimal decellularization method and its
efficacy is crucial for clinical success or failure. Equally important, removal of cell rem-
nants and chemical treatment trace are important to prevent a host response (Crapo
et al. 2011).
Focusing on vascular tissue, the preservation of collagen and elastin is crucial to
maintain the physiological elasticity necessary to withstand the pulsatile blood flow.
ECM scaffolds present a multifunctional structure with the ability to induce cell
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attachment, proliferation, migration, differentiation and maturation, even of stem cells
(Guruswamy Damodaran and Vermette 2018), due to cell signaling.
Molecules such as growth factors, glycans, bioactive cryptic peptides and natu-
ral proteins like collagen and fibronectin, promote biological activities such as, cell
growth, function, differentiation, angiogenesis, anti-angiogenesis, antimicrobial effects
and chemotactic effects (Kawecki et al. 2018). Indeed, many studies have demonstrated
that proteoglycans from the ECM are involved in these molecular events (Schmidt and
Baier 2000; Wight et al. 1992). This specific properties, would present an advantage
to using decellularized materials instead of other biological or synthetic materials (Gu-
ruswamy Damodaran and Vermette 2018).
Taken all together, there are two main advantages as a rationale for using ECM
as a blood vessel scaffold. The first one consists in the fact that after the removal of
cells, the decellularized scaffold that constitute the ECM can maintain the mechanical
properties of the natural vessels, if correctly treated, to withstand changes in blood
pressure (Lin et al. 2018). The second one is the ECM’s influence on the cells behavior,
mitogenesis and chemotaxis (Bornstein and Sage 2002; Vorotnikova et al. 2010) and
direct cell differentiation are verified (Allen et al. 2010; Barkan et al. 2010; Cheng
et al. 2009; Cortiella et al. 2010; Ross et al. 2009; Sellaro et al. 2010; Stern et al.
2009). Furthermore, some researchers suggest that after implantation, the biological
ECM scaffold induces tissue remodeling and regeneration in the host since they possess
immunomodulatory activities (Kawecki et al. 2018; Parekh et al. 2009; Valentin et al.
2010; Xu et al. 2010).
Attending the decellularization characteristics, it is a promising approach to pro-
duce small-diameter vascular grafts (Keane et al. 2015; Taylor et al. 2018).
1.4.1 Decellularization agents and techniques
Decellularization protocols have been developed for almost each body tissue. The
decellularization method can be different but the aim is always to obtain a balance
between the most effective cell removing action and the maximum possible preservation
of the native ECM structure (Keane et al. 2015). Since any decellularizing procedure
involves the destruction of the ECM, it should be emphasized once more that the
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negative impact of cell removal methods is tolerable if the undesirable effects in the
mechanical properties will be minimized or completely avoided (Crapo et al. 2011;
Guruswamy Damodaran and Vermette 2018).
Different factors such as the amount of cells colonizing the biomaterial (e.g., the
liver vs. tendon), the density of ECM structure (e.g., dermis vs. adipose tissue), the fat
content (e.g., the brain vs. bladder), and the thickness (e.g., dermis vs. pericardium)
affect the chosen decellularization process (Kawecki et al. 2018).
Most decellularization protocols involve a physical treatments such as agitation,
sonication, mechanical pressure, or freeze-thawing procedures, in order to disrupt the
cell membrane, in combination with extensive washing steps and further chemical pro-
cessing with ionic solutions and various detergents or/and enzymes (Hinderer et al.
2016).
1.4.2 Physical methods
The main advantage of tissue decellularization by means of physical methods over
chemical methods is the lack of introduction of potentially toxic chemicals to the tissue.
However, physical methods as cell removal agents require prolonged exposure of the
tissues to the agent, which can cause the degradation of the material. For this reason, it
is common to include a physical method step in the decellularization protocol (Kawecki
et al. 2018).
Physical methods of decellularization include multiple freeze-thaw cycles to dis-
rupt the cellular components, agitation during immersion in chemical solution, and
application of pressure or supercritical fluids (Taylor et al. 2018).
Freeze-thaw cycles have a lysis cell effect with no significant alteration on the me-
chanical properties of the ECM. As all decellularization methods, the tissue micro and
nano structure could be modified, therefore this method can be used only if the changes
are acceptable. The method limitation is the elimination of cell membranes and in-
tracellular element fragments; therefore, it is common to combine it with chemical
methods, reducing the chemical amount required for the lysis step.
In order to increase the methods efficiency, the freezing and thawing cycles are usu-
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ally repeated. However, a single cycle may reduce adverse immune reactions, including
leukocyte infiltration in vascular ECM scaffolds (Crapo et al. 2011; Keane et al. 2015).
Since these cycles may increase the loss of protein and cause other structural changes
(Yang et al. 2010-10), it is suggested to use a cryoprotectant such as 5% trehalose to
minimize these adverse effects, without impeding cell lysis.
This method is frequently used for tissues characterized by fine structures such as
the bladder, the pericardium, and the amnion (Kawecki et al. 2018). For load-bearing
robust tissues, the effect of freeze-thaw processing is minimal from the mechanical
properties’ point of view (Elder et al. 2010; Jackson et al. 1988).
Another physical decellularization method is sonication. The ultrasounds cause the
cell lysis for a cell-free ECM scaffold production.
Freezedrying method has a decellularization effectiveness similar to that of cyclic
freezing and thawing, but this method also presents a raised demonstrated effectivity
for long-term storage of biological materials. The removal of defaulting cell membranes,
nucleic acids, and other cellular organelles can level off at unsatisfactory levels (Kawecki
et al. 2018).
Non-thermal irreversible electroporation method (NTIRE) consists in the applica-
tion of electrical pulses across the tissue, these induce the formation of micropores
in the cell membrane due to the destabilization of the electrical potential across the
membrane (Lee 2005; Lee and Kolodney 1987).
Usually this technique is used in vivo, where the micropores cause loss of cell home-
ostasis and lead to cell death. In vivo experiments in rat carotid arteries demonstrated
that the cellular remnants were slowly removed from the tissue over a period of days,
leaving an acellular tissue approximately three days after NTIRE treatment (Phillips
et al. 2010). The mechanisms for the cellular removal are not clear. By selecting ap-
propriate parameters to reduce heat generation, the integrity and morphology of the
remaining ECM appears to be retained, which allows for recellularization by host cells.
The biggest NTIRE limitation is that the decellularization process would need to
occur in vivo because the cells removal is caused by the organisms’ immune system.




The number of cellular remnants retained within the tissue is to be determined.
As discussed previously, ECM scaffolds that have not been thoroughly decellularized
promote a very different, less desirable host response than those that have been cleared
of cell remnants (Crapo et al. 2011).
1.4.3 Chemical agents
Chemical agents are often used combined with physical methods. According to
their chemical properties, the most effective chemical agent combination, for removing
cells while preserving the ECM, will be different for each tissue.
Acids and bases cause or catalyze hydrolytic degradation of biomolecules which is
important for the decellularization effectiveness but, they have a negative impact on
the ECMs mechanical strength and can also denature ECMs components including
GAGs, collagen, and growth factors (Keane et al. 2015).
Accordingly, Tsuchiya et al. (2014) confirms that the utilization of acidic or alkaline
solutions during decellularization requires a balanced approach to achieve effective
decellularization without severe detriment of the ECM constituents. Studies compared
the effectiveness of cell and cytoskeletal protein removal with 8 mM CHAPS solutions
at different pH values. The cell removals efficiency is higher if the pH value increases
however, highly alkaline CHAPS (pH 12) disrupted architecture and resulted in a more
fibrotic response compared to that of lungs decellularized in 8 mM CHAPS at pH 8
and pH 10 following subcutaneous implantation. In the same way, Mendoza-Novelo
et al. (2011) showed that a calcium oxide treatment results in a dramatic reduction in
GAG content and altered the viscoelastic properties of pericardial tissue.
For this reason, it is important to optimize the dose and exposure time when acids
are used for decellularization.
Commonly used alkaline bases include ammonium hydroxide, sodium sulfide, sodium
hydroxide, and calcium hydroxide and acids frequently used are deoxycholic, acetic and
peracetic (Keane et al. 2015). Is important to remark the use of peracetic acid to ster-
ilize decellularized scaffold materials, which is a method approved by the FDA and the
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European Union (EU) for medical devices, in addition with its decellularization agent
action by removing residual nucleic acids with minimal effect on the ECM composition
and structure (Gilbert et al. 2008; Hodde et al. 2007; Hodde and Hiles 2002).
Osmotic pressure solutions affect the cell structure through the lysis of the cellular
membrane.
Different kind of solvents can be used such as decellularized agent. In this context,
alcohols can diffuse into the cell and replace the intra cellular water, hence, the cells lyse
by dehydration. Moreover, the nonpolar carbon chain of alcohols dissolves nonpolar
substances such as lipids (Montoya and McFetridge 2009). In fact, alcohols such as
isopropanol, ethanol, and methanol are more effective than lipase in removing lipids
from tissue and are capable of rendering adipose tissue lipid-free in a relatively brief
period of time (Crapo et al. 2011).
Care must be taken in treating tissues with alcohols such as ethanol and methanol
due to their use as tissue fixatives in histology, they alter the collagen structure by
crosslinking the ECM (Keane et al. 2015).
Another method of removing lipids during decellularization is the use of acetone,
but care should be taken when utilizing this solvent because it is a fixative tissue. This
can cause damaging in the EMCs structure due to the crosslinks formed by acetone in
the EMC, producing a stiffer scaffold (Cole 1984; Jamur and Oliver 2010).
Tributyl phosphate (TBP) is an organic solvent with viricidal properties (Horowitz
et al. 1992). Recent studies (Cartmell and Dunn 2000; Deeken et al. 2011; Woods and
Gratzer 2005) highlight that TBP appears to be more effective that detergents such as
SDS and Triton X-100 to decellularize tendon and ligament tissues. Moreover, collagen
matrix, GAGs, and biomechanical properties (including tensile strength and elasticity)
were not significantly altered. Although residual cytoskeletal proteins (e.g., vimentin)
were not completely removed, TBP is a viable option that warrants further study for
other tissue types (Keane et al. 2015).
Triton X-100 as a detergent, solubilizes the cell membrane and dissociates DNA
from proteins which is important in order to remove the cell material from the tissue.
Nevertheless, the detergent can also disrupt the ECM proteins and this depends on
the exposure time (Crapo et al. 2011). Triton X-100 is the most studied non anionic
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detergent and it is effectively capable of expelling cell debris from thicker tissues, such
as heart valves (Kawecki et al. 2018) on the other hand, some studies demonstrated
that Triton X-100 had a poor cell removal capacity for blood vessels decellularization
(Keane et al. 2015).
Sodium dodecyl sulfate (SDS), sodium deoxycholate (SDC) and Triton X-200 are
the most commonly used ionic detergents. They are used as decellularizing reagents
due to their ability to solubilize cytoplasmic membranes, lipids, and DNA (Keane
et al. 2015). If compared to Triton X-100, SDS appears more effective in the re-
moval of cell nuclei and acid, while maintaining the mechanical characteristics of the
natural tissue/organ in organs including aorta, veins, heart, kidneys and urethra (Gu-
ruswamy Damodaran and Vermette 2018). Its use in the decellularization protocol can
make a difference between complete and incomplete cell nuclei removal (Crapo et al.
2011).
The use of SDC agent to decellularize is controversial. Some researches demon-
strated that SDC treatment obtains an incomplete nuclei removal and its effect can
adversely affect the ECM structure and composition (Roosens et al. 2016; Zvarova
et al. 2016). By contrast, Gilpin et al. (2014) suggests that SDC may be an effective
decellularization factor when applied to tissues and organs that are less dense and have
a clear ECM structure, such as the heart valve.
Another detergent proposed for decellularization is 3[(3-cholamidopropyl) dimethyl-
ammonio]-1-propanesulfonate (CHAPS) which combines non-ionic and ionic detergent
properties, it is consider a zwitterionic detergent.
Blood vessels treated with CHAPS have histologically unaltered collagen and elastin
morphologies, and the collagen content remains comparable to that of the native artery
(Boccafoschi et al. 2017a), due to its net zero electrical charge on the hydrophilic groups.
Furthermore, it retains more collagen, GAGs, and elastin than SDS while still removing
95% of nuclear material (O’Neill et al. 2013; Petersen et al. 2012, 2010).
Using enzymes to decellularize materials allows the removal of specific cell com-
ponents such as cell-cell attachments, cell-ECM attachments, or nucleic acid-ECM at-
tachments, with specific enzymes such as nucleases, collagenases, and proteases (Taylor
et al. 2018). For all that, complete cell removal by enzymatic treatment alone is prob-
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lematic and enzyme residues may restrain the recellularization or evoke an adverse
immune response.
Unremoved nucleic acids may play a role in the immune response after implanta-
tion. Hence, reducing the DNA and RNA content in the tissue is essential for a good
decellularization result. In this context, nucleases such as DNases and RNases cleave
nucleic acid sequences and can be efficient in the removal of nucleotides after cell lysis
in tissues (Kawecki et al. 2018). For instance, these, combined with SDS, produced a
completely acellular rat aortic valve (Grauss et al. 2005) which highlights the detergent
combination steps.
Trypsin is the most common protease used in decellularization protocols. Its func-
tion consists in selectively cleaving cell adherent proteins on the carboxyl group of
lysine and arginine to detach cells from the tissue surface. Trypsin action, in com-
parison to that of detergents, presents better preservation of GAG content, but it is
more destructive to elastin and collagen structures, this can be associated to changes
in mechanical properties. For this reason, concentration and exposure time to trypsin
should therefore be set with caution, moreover, to improve the treatment penetration
of subsequent decellularization agents, this enzyme should be used as an initial step
of the treatment (Crapo et al. 2011). Is known that trypsin does not induce a cyto-
toxic effect because it is commonly used in vitro cell culture, this fact represents an
advantage when used in tissue engineering (Kawecki et al. 2018).
Dispase II is a protease used specifically for epithelial cells and its action in the
membrane focuses on cleaving fibronectin and collagen IV. Temperature and pH fac-
tors compromise its enzymatic activity, which is just effective under physiological con-
ditions. Combination of trypsin and dispase presented a better decellularization effect
in comparison to using one of them alone. This results were confirmed for different
tissues (Kawecki et al. 2018). Its use is also recommended on the first steps of the de-
cellularization process and it is used in porcine dermis and cornea tissues (Song et al.
2013; Xu et al. 2017) nevertheless, subsequent treatments or use of agents are necessary
in order to obtain an adequate decellularization.
Collagenases group is an alternative enzymatic decellularization process used only
when the material bioprosthesis does not require the maintenance of the integrity of
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the collagen structure for the intended clinical application (Flynn 2010; Perea-Gil et al.
2015).
Ethylenediaminetetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA)
are chelating agents commonly used to dissociate cells from the ECM, these reagents
are typically used in combination with trypsin or detergents because chelating agents
alone are not sufficient for superficial cell removal even with agitation. In order to
minimize the destructive effects on the ECM it is desirable to limit the duration of the
exposure to trypsin-EDTA treatments.
An alternative to detergents was individuated on latrunculin B, a marine toxin.
This substance allows to preserve the collagen fibrillar ultrastructure largely uncharged
even though GAGs were reduced by around 40%. The latrunculin B decellularization
efficiency in combination with hypertonic solutions and DNase was demonstrated for
skeletal muscle tissue (Keane et al. 2015).
1.4.4 Techniques for agent’s application
Agitation and immersion in chemical, detergent, and/or enzymatic solutions are
the classical techniques for tissue decellularization when the material is not a natural
vasculature used to perfuse the organ. The duration of the protocol depends on the
tissues thickness and density, on the detergent used and on the intensity of agitation
and it was described for different tissues, including heart valves, blood vessel, skeletal
muscle/tendon, peripheral nerve, spinal cord, cartilage/meniscus, trachea, esophagus,
dermis, and urinary bladder (Crapo et al. 2011). However, this method may damage the
ultrastructure and the integrity of the ECM scaffold and another optimal alternative
could exist (Kawecki et al. 2018).
The properties of supercritical fluids, in particular carbon dioxide, such as low
viscosity and high transport characteristics for a tissue decellularization allow to obtain
simple and short protocols.
The advantages of supercritical gas decellularization include the use of an inert
substance for cell removal and minimal alteration of ECM mechanical properties. Fur-
thermore, tissues can be obtained in dry conditions following decellularization and this




Perfusion technique is used for hollow tissues such as vessels and intestine tract to
produce a transmural pressure gradient, designated as a convective flow in order to
accelerate and improve the efficency of delivering cell-lysing agents into the tissue and
forcing cellular debris out of the tissue (Keane et al. 2015).
Bolland et al. (2007) and Montoya and McFetridge (2009) showed convective flow
degraded collagen to a lesser extent than agitation as assessed by hydroxyproline quan-
tification, and collagens I and IV, laminin, and GAG were retained along with some
intracellular proteins, and mechanical properties were unaffected by the decellulariza-
tion process.
Perfusion decellularization, using the natural vasculature, is the best approach for
organ decellularization as it can minimize ECM damage due to excessive mechanical
forces, while maximizing the delivery of decellularizing solutions to deeper parts of the
organ (Taylor et al. 2018).
Table 5 contains the highlights of decellularization agents and techniques.
Agent/technique Mode of action Effects on ECM
Physical and miscellaneous agents
Temperature
(freezing and thawing)
Intracellular formation of ice
crystals leads to disruption of
cell membrane
Ice crystal formation can lead to
disruption or fracture of ECM
Sonication Ultrasound cell lysis
Ultrasound can lead to disrup-
tion or fracture of ECM
Freeze-drying
Effective method for long-term
storage of biological materials
Electroporation
Pulsed electrical fields disrupt
cell membranes





nents of cells, disrupts nucleic
acids, tend to denature proteins




Cell lysis by osmotic shock, dis-
rupt DNA-protein interactions
Effectively lyses cells, but does
not effectively remove cellular
residues
Table 5: Summary of the different decellularization agents and techniques (Boccafoschi
et al. 2017a; Crapo et al. 2011; Kawecki et al. 2018). Continued on next page.
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Agent/technique Mode of action Effects on ECM
Solvents
Alcohols
Cell lysis by dehydration, solu-
bilize and remove lipids
Effectively removes cells from
dense tissues and inactivates py-
rogens, but crosslinks and pre-
cipitates proteins, including col-
lagen
Acetone
Cell lysis by dehydration, solu-
bilizes and removes lipids
Effectively removes cells from
dense tissues and inactivates py-
rogens, but crosslinks and pre-
cipitates proteins, including col-
lagen
Tributyl phosphate (TBP)
Forms stable complexes with
metals, disrupts protein-protein
interactions
Mixed results with efficacy de-
pendent on tissue, dense tissues
lost collagen but impact on me-
chanical properties was minimal
Nonionic detergents
Disrupt DNA-protein interac-
tions, disrupt lipid-lipid and
lipid-protein interactions, and,
to a lesser degree, protein-
protein interactions
Triton X-100
Mixed results with efficacy de-
pendent on tissue, more effec-
tive cell removal from thin tis-
sues, some disruption of ultra-
structure and removal of GAG,
less effective than SDS
Ionic detergents
Solubilize cell and nucleic mem-
branes, tend to denature pro-
teins
Sodium dodecyl sulfate (SDS)
Effectively removes nuclear rem-
nants and cytoplasmic proteins
from dense tissues, tends to dis-
rupt ultrastructure, removes gag
and growth factors and damages
collagen
Sodium deoxycholate (SDC)
Mixed results with efficacy de-
pendent on tissue thickness,
some disruption of ultrastruc-
ture and removal of GAG
Table 5: Summary of the different decellularization agents and techniques (Boccafoschi
et al. 2017a; Crapo et al. 2011; Kawecki et al. 2018). Continued on next page.
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Agent/technique Mode of action Effects on ECM
Triton X-200
More effectively removes cells
from thin tissues but with
greater disruption of ultrastruc-
ture compared to other deter-
gents
Zwitterionic detergents





Effectively removes cells with




Effectively removes cells with




Catalyzes the hydrolysis of ri-
bonucleotide and deoxyribonu-
cleotide chain
Difficult to remove from tis-
sue, could invoke an immune re-
sponse
Trypsin
Cleaves peptide bonds on the c-
side of Arg and Lys
Prolonged exposure can dis-
rupt ECM ultrastructure, re-
moves ECM constituents such
as collagen, laminin, fibronectin,
elastin, and gag, compared to
detergents, as lower gag removal
Dispase
Cleaves specific peptides, mainly
fibronectin and collagen iv
Prolonged exposure can disrupt
ECM ultra-structure, removes
ECM constituents such as fi-
bronectin and collagen IV
Collagenases Cleaves specific collagen groups





Typically used with enzymatic
methods (e.g., trypsin) but can
be used with other agents; inef-
fective when used alone
Chelating agents bind metallic
ions, thereby disrupting cell ad-
hesion to ECM
Techniques to apply agents
Agitation
Can lyse cells, but more com-
monly used to facilitate chemical
exposure and removal of cellular
material
Aggressive agitation or sonica-
tion can disrupt ECM
Pressure gradient across tissue
Facilitates chemical exposure
and removal of cellular material
Pressure gradient can disrupt
ECM
Table 5: Summary of the different decellularization agents and techniques (Boccafoschi
et al. 2017a; Crapo et al. 2011; Kawecki et al. 2018). Continued on next page.
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Agent/technique Mode of action Effects on ECM
Supercritical fluid
Pressure can burst cells, super-
critical fluid facilitates chemical
exposure and removal of cellular
material
Pressure necessary for supercrit-
ical phase can disrupt ECM
Perfusion
Facilitates chemical exposure
and removal of cellular material
Pressure associated with perfu-
sion can disrupt ECM
Table 5: Summary of the different decellularization agents and techniques (Boccafoschi
et al. 2017a; Crapo et al. 2011; Kawecki et al. 2018)
More specifically, Table 6, summarizes the influences of the different decellulariza-






Effect on mechanical property
with respect to native tissue
Deoxycholate Porcine carotid artery,
abdominal aorta
No effect (Murase et al. 2006; Pelle-
gata et al. 2013)
Compliance SDS Ovine carotid artery Decrease (Mancuso et al. 2014)
Trion X-100 Ovine carotid No effect (Mancuso et al. 2014)
Deoxycholate Porcine carotid artery,
abdominal aorta
No effect (Pellegata et al. 2013)
Young’s
modulus
Triton X-100 Bovine jugular vein Decrease (Lü et al. 2009)
SDS Human umbilical vein No effect (Abousleiman et al. 2008)
Triton X-100 Porcine carotid artery
Increase of stiffness (Sheridan et al.
2012)






Porcine thoracic aorta No difference (Zou and Zhang 2012)
Trypsin + EDTA Porcine thoracic aorta No difference (Zou and Zhang 2012)





Fetal pig aorta, human
saphenous vein, human
umbilical artery
No difference (Chen et al. 2013; Liu
et al. 2008; Schaner et al. 2004)
Table 6: Influence of different decellularizing methods on blood vessel substitutes me-
chanical properties (Boccafoschi et al. 2017b).
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Even though decellularized matrices have proved to be a very interesting material to
use as scaffold for tissue engineering, they present some major flaws given by their poor
mechanical properties. To give these materials mechanical properties similar to those
of the native tissue some chemical crosslinkers can be used. It is necessary to evaluate
that the crosslinker is not toxic and make sure that its use does not adversely affect








Amphipathic agent, ECM, sta-
ble and resistant to chemical and
enzymatic degradation
Polymerization in aqueous solu-
tions, depolymerization in the
body of the recipient, untimely
calcification, cytotoxicity, im-




of the immune response




Forms multiple bonds, exhibits






A bifunctional reagent of re-
duced calcification, low cytotox-





High material stability, low cy-









ity, low cytotoxicity and calcifi-




Possible application to the
preparation of biomaterials with




High stability of biomaterials
degrade, low cytotoxicity, bio-
material with morphology very
well preserved
No data
Table 7: Selected crosslinking agents and their influence on properties of biomaterials
(Kawecki et al. 2018).
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1.5 Clinical trials of vascular tissue engineering
Regarding clinical trials for vascular tissue engineering some major concerns must
be kept in mind. Firstly, some surgical issues must be evaluated: the type of treatment
given before, during and after the surgical procedure, the diameter of the prothesis
which must be identical to that of the native tissue, and the type of prothesis control
used. Secondly, the best results come from animal trials carried out using xenograft



















































88% up to 3
months in ba-
boon; 83% up
to 1 month in
dog
No dilatation, calcification and
intimal hyperplasia; Endothe-
lialization at both near anasto-
motic sites and midgraft in both
grafts. SMC infiltration by 6
months in baboon model and by













by 24 weeks with elastin de-
position evident; No evidence
of dilatation or mineralization.
Mid-graft lumen diameter was
unchanged; Extensive recellular-











Neointima (ECs) and neomedia












at 3 and 6
months
No calcifications, loss of burst
strength, or outflow stenosis;
Developing endothelium at lu-
men and SMCs








Significantly longer average pa-




















Cell infiltration at whole layer;
Extracellular matrix mature and





















No No No No Rat carotid artery
100% at 3
weeks
Cell attachment at luminal sur-
face and cell infiltration at lumi-
nal wall
Table 8: Summary of in vivo performance of variant decellularized vascular grafts since




The scale-up/industrialization process is part of a more complex process of technol-
ogy transfer from the laboratory to an industrial scale. Scale-up enters into the science
of chemical engineering and it attempts the obtaining of a product in the laboratory
with the same characteristics and performance as a larger scale production. Also, other
processing factors, such as the reproducibility of the process or its control need to be
considered. From the normative point of view, in the specific case of the biomedical
field, issues such as sterility and the laws that affect these products are important to
study throughout the production cycle, from raw materials to the production environ-
ment and the chain of material transport. The whole process must be optimized, not
only from an engineering point of view but also from an economic point of view, which
will be reflected in the economic feasibility study.
In this context, due to the product’s origin, it is important to define decellulariza-
tion, this has been introduced and further explored by Badylak et al. who introduced
the criteria which were later introduced in the regulation concerning these kinds of
products. These criteria are: (1) complete absence of visible nuclear material upon
histological examination (haematoxylin and eosin and 4′-6-diamidino-2phenylindole
(DAPI) stains); (2) less than 50 ng of dsDNA per mg ECM dry weight; and (3)
remnant DNA molecules shorter than 200 bp (Crapo et al. 2011). In addition to these
criteria, others have been added in order to transfer this into an industrialized process,
these include: the lack of intracellular membrane compartments (e.g., mitochondria),
the lack of cell membrane elements, the presence of unremoved and undamaged ECM
elements (collagen, GAG, fibronectin, etc.) the lack of cytotoxicity of the obtained
ECM scaffold (Kawecki et al. 2018).
Moreover, in order to be able to produce commercialized products, the medical
devices must undergo a sterilization process. In this context, depyrogenation is a
mandatory method which eliminates endotoxins, intact viral DNA and bacterial DNA
that may be present. For all this, biological security requires a final sterilization of
the tissues prior to clinical application and the usual sterilization procedures include
ethylene oxide, peracetic acid, slightly acidic electrolyzed water, gamma irradiation,
electron beam irradiation, and supercritical CO2.
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Acids and solvents exhibit insufficient penetration through the material and could
change the mechanical properties because they have crosslinking tendencies (Gorschewsky
et al. 2005; Hodde and Hiles 2002; Matuska and McFetridge 2015-02). Peracetic acid
is the most prevalent due to its GAGs preservation, DNA removal efficiency and the
ability to maintain collagen’s mechanical integrity.
The use of ethylene oxide as a sterilization agent is controversial. Some in vitro
results show that its use does not affect the cell attachment to ECM or the stimulation
of growth factors’ secretion by fibroblasts (Hodde et al. 2007). On the other hand, it
is classified as a mutagen and as a carcinogen and its elimination is crucial to obtain
a secure implantable product. The use of ethylene oxide for terminal sterilization of
biologic scaffolds should be considered carefully.
Gamma irradiation exposure is a standard sterilization process, however, dosages
lower than 15 kGy increase the strength and modulus of the ECM due to the collagen
cross link (this phenomenon occurs even at 5 kGy doses) but, at higher dosages it pro-
portionally changes the tissue properties. Gamma irradiation also causes a negative
effect on the ability of cells to attach to the ECM in vitro (Matuska and McFetridge
2015-02), the residual lipids to become cytotoxic and it accelerates enzymatic degra-
dation (Moreau et al. 2000-02). Nonetheless, many authors recommend sterilization
by gamma radiation or electron beam radiation as an effective and safe sterilization
process (Dziedzic-Goclawska et al. 2005; Nguyen et al. 2007).
Supercritical carbon dioxide (SC-CO2) is already studied as a decellularization
method and recently its application in the sterilization phase has obtained satisfactory
results in terms of non-toxicity residues and minor changes in mechanical properties
when compared with other sterilization methods (Donati et al. 2012; Qiu et al. 2009).
However, some works evidence negative impacts on the structure and function of ECM
proteins (Wimmer and Zarevúcka 2010).
1.6.1 Clinical products
Now, several clinical products composed of ECM are available in the market. The
allogenic or xenogeneic tissue sources are dermis, urinary bladder, small intestine,
mesothelium, pericardium, and heart valves, and from several different species. The
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applications of these biomaterials include, for example, hernia reconstructive surgery,
soft tissue augmentation, breast reconstruction, and wound healing. Table 9 shows
available commercial products composed of decellularized tissues. In USA, the FDA
classifies these products, such as medical devices, which require to apply the guidelines
regarding bacterial load regulated by ISO/DIS 1135-1, ISO/DIS 1137-1 rules (Keane
et al. 2015).
Product (Manufacturer) Tissue Source Application focus
Cor™Patch®
(Cardiovascular Inc.)
Porcine small intestine Pericardium, cardiac tissue
Perimount® (Edwards
Lifesciences LLC)
Bovine pericardium Valve replacement
Hancock® II, Mosaic®,
Freestyle® (Medtronic Inc.)
Porcine heart valve Valve replacement
Magna Mitral Ease (Edwards
Lifesciences LLC)
Porcine heart valve Valve replacement
Epic™, SJM Biocor® (St. Jude
Medical Inc.)
Porcine heart valve Valve replacement
Omniflow® II (LeMaitre Vascu-
lar Inc.) *Not approved for sale
in the United States
Cross-linked ovine collagen
Peripheral revascularization,
Arteriovenous fistula (AV access)





Artegraft® (Artegraft Inc.) Bovine carotid artery AV access
CryoGraft® (CryoLife Inc.) Human descending aorta Aneurysm reconstruction
ProCol® (LeMaitre
Vascular Inc.)
Bovine mesenteric vein AV access
CryoArtery® (CryoLife Inc.) Human femoral artery Peripheral revascularization, AV access




Management of wounds pressure ulcers,
venous ulcers, chronic vascular ulcers,
trauma wounds (abrasions, lacerations,
second-degree burns, skin tears), draining
wounds, surgical wounds
Table 9: Available commercial decellularized products. Continued on next page.
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Product (Manufacturer) Tissue Source Application focus
GraftJacket® (Acelity L.P. Inc.,
Texas, USA)
Acellular human dermis





Kalamazoo, MI 49002 USA)
Acellular human dermal matrix
Chronic wounds and soft tissue
reconstruction
Alloderm® (Allergan plc
[NYSE: AGN, Dublin, Ireland])
Human dermis Breast reconstruction post masectomy
Strattice™ (Allergan plc
[NYSE: AGN, Dublin, Ireland])
Porcine dermis




Decellularized human dermis Wound healing
MatriStem®
(ACell, Columbia, USA)
Porcine Urinary Bladder Matrix Wound healing and care, surgical repairs
Biodesign® (COOK MEDICAL
INC., Bloomington, IN, USA)
Porcine small intestine
submucosa
Soft tissue, hiatal hernia
Lyoplant® (Aesculap, Inc.,
Center Valley, PA, USA)




Human acellular dermis Tendon, breast
Strattice™ (Lifecell Corp.) Porcine dermis Soft tissue
Zimmer Collagen Repair Patch™
(Zimmer Inc.)
Porcine dermis Soft tissue
TissueMend® (Stryker Corp.) Fetal Bovine dermis Soft tissue, tendon repair surgery
FortaFlex®, BioSTAR®
(Organogenesis Inc.)
Porcine small intestine Soft tissue and cardiac applications
Meso BioMatrix™
(Kensey Nash Corp.)
Porcine mesothelium Soft tissue, wound healing
CopiOs® (Zimmer Inc.) Bovine pericardium Dentistry, bone healing
Lyoplant®
(B. Braun Melsungen AG)






Table 9: Available commercial decellularized products. Continued on next page.
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Product (Manufacturer) Tissue Source Application focus
MIRODERM®; (Miromatrix
Medical Inc., Eden Prairie, MN)
Porcine liver
Wound management; venous ulcers,
vascular ulcers
MIROMESH® (Miromatrix
Medical Inc., Eden Prairie, MN)




Table 9: Available commercial decellularized products.
The success of ECM clinical products, confirmed by more than 20 years of commer-
cialization (Guruswamy Damodaran and Vermette 2018), opens the door for develop-
ing functional organs to reduce the number of patients awaiting life-saving transplants
(Taylor et al. 2018). Some companies, like Miromatrix Medical Inc. (Eden Prairie,
Minneapolis) a USA-based biotechnology company or AxoGen Inc. (Alachua, Florida)
from USA, are developing decellularized liver, kidney and nerve connectors. Humacyte
Inc. (Morrisville, North Carolina), develops acellular grafts to repair vascular damages.
Some of their products are under phase III clinical trials (Guruswamy Damodaran and
Vermette 2018).
Focusing on currently decellularized vascular grafts on the market, such as Artegraft®,
Solcograft, ProCol®, and SynerGraft® reported in Table 9, most of them are used for
vascular access during hemodialysis or peripheral arterial bypass.
Although already on the market, their performances are not satisfactory due to
graft-related thrombosis, infection, and aneurysm. For this reason, currently decel-
lularized xenogeneic grafts offer only non-inferior results compared with alternative
synthetic conduits. High cost, when compared with synthetic grafts, and their low
performances, entails that they have not been widely used in the clinic (Pashneh-Tala
et al. 2016).
For these reasons, there is a continuous pursuit on the application of decellularized
ECM in small-diameter vascular tissue engineering. These studies evaluate matrices
obtained from human umbilical veins and arteries, porcine’s arteries like the carotid,
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the radial, the saphenous, the iliac, the small intestine submucosa and the bovine ureter
(Lin et al. 2018).
1.6.2 Regulation aspects
The biological scaffolds commercialized reported on the Table 9 are marketed under
the category of 510(K) of the FDA, for the USA market, or under CE medical devices
class III category for European market. The EU commission regulation N0 722/2012
of August, 8th, 2012 concerning particular requirements laid down in Council Direc-
tives 90/385/EEC and 93/42/EEC with respect to active implantable medical devices
and medical devices manufactured utilizing tissues of animal origin, has adopted a
regulation based on: the original requirements, and the maintenance of a high level
of safety and health protection against the risk of transmitting animal spongiform
encephalopathies.
The regulation also considers that the active implantable medical devices and med-
ical devices of class III are subject to the conformity assessment procedures, prior
to being placed on the market or put into service, demanding the adoption of more
detailed specifications relating to the risk analysis and management.
Regulation establishes requirements in relation to the placing on the market and/or
putting into service of medical devices, including active implantable medical devices,
manufactured utilizing animal tissue and their derivatives, originating from bovine,
ovine and caprine species, deer, elk, mink and cats. In the case of collagen, gelatin and
tallow used for the manufacturing of medical devices shall meet at least the require-
ments as fit for human consumption.
The regulation also establishes that the manufacturer of medical devices or his
authorized representative shall carry out the risk analysis and risk management scheme
before lodging an application for a conformity assessment.
Conformity assessment procedures for medical devices shall include the evaluation
of compliance of the devices with the essential requirements into the current directives
and the requirements laid down in this Regulation.
The new two European Health Products Regulations came into force on May, 26th,
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2017. The first one, the Regulation (EU) 2017/745 of medical devices, which modifies
Directive 2001/83/EC and subsequent derived regulations, repealing Council Directives
90/385/EEC and 93/42/EEC, will be applicable from May, 26th, 2020. The second one,
Regulation (EU) 2017/746 of in vitro medical devices, which repeals both Directive
98/78/EC and the decision of the commission 2010/227/EU, it will applicable from
May, 26th, 2022.
This is the detail of some of the most important changes and novelties contained
in the Sanitary Products Regulation:
• Transitional period: Since a transitional period of three years is expected from
its entry into force, since May, 26th 2017, and until May, 26th, 2020, both reg-
ulatory frameworks may coexist and certificates may be issued in accordance
with the provisions of the new Regulation or the old Directives 90/385/EEC and
93/42/EEC. In the latter case, the certificates will have a maximum validity of
5 years and they will be considered invalid as of May, 27th, 2024. In any case,
any product introduced on the market in accordance with the requirements of
the old Directives can only continue to be marketed or be put into service until
May, 27th, 2025.
• Specification of the definition of health products: The definition of ”health prod-
uct” is specified and defined. The definition includes clearly computer programs,
implants or reagents, and establishes the need that the manufacturer has fore-
seen a specific medical purpose. In addition, the Regulation clarifies that sanitary
products, ”control products or support for conception”, as well as products specif-
ically intended for cleaning, disinfection or sterilization of medical devices and
their accessories are within the scope of this Regulation.
• Reinforcement of guarantees in all stages: The pre-commercialization and post-
marketing guarantees of medical devices are reinforced. In relation to pre-commercia-
lization guarantees, the role of the European Commission of categorizing and
classification of products is increased, and it should no longer be limited to ac-
tion if a Member State previously requests it, but it must do so ex officio. For
this purpose, the Member State will count on the help of a Coordination Group
of Health Products with European experts.
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• Increased transparency and traceability: New measures are introduced aimed at
increasing transparency and traceability:
1. A European Union Global Database (EUDAMED) for medical devices is
created, a European portal that is essential for the practical application of
the Regulation since it must include the new electronic systems created by
the Regulation: the electronic registration system of products, the Unique
Product Identification (UDI) database, the electronic system for registering
economic agents, the monitoring and post-marketing monitoring system and
the electronic market control system. This database must be up and running
by March, 25th, 2020.
2. The Product Registry is created and the Unique Product Identification sys-
tem (UDI) is established to guarantee the traceability of the products at
any time, which obliges manufacturers to assign and maintain an UDI for
all their products.
3. The Registry of economic operators is created in which all manufacturers,
authorized representatives and importers must register before introducing a
sanitary product on the market.
4. All manufacturers of implantable products are obliged to accompany the im-
plant card product and information that allow the identification of the prod-
uct, the warnings or measures that the patient or health professional must
take, and the regulation also obligates the Member States for demanding
health centers to provide the mentioned card and the required information
to patients.
• Definition of obligations of the economic operators: The obligations and respon-
sibilities of each one of the economic agents that were not sufficiently detailed
in the previous regulation, are here specified in detail; forcing manufacturers to
establish a quality assurance system, a system to obtain and review data after
commercialization of products, to establish measures to offer sufficient financial
coverage adapted to the type of risk, type of product and size of the company,
as well as having a technician responsible for compliance with the regulations,
who may be trained in law, medicine, pharmacy, engineering or other scientific
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discipline, and one year of professional experience in regulatory matters or in
quality management systems related to medical devices.
Taken all together, several aspects are important from the product performances
point of view, for example cytotoxicity, sensitization, haemocompatibility (hemolysis,
thrombogenicity), pyrogenicity, implantation, genotoxicity, carcinogenicity, reproduc-
tive and developmental toxicity, degradation assessments. However, other aspects are
crucial for the industrialization process or processability. In particular, low manu-
facturing costs, availability of large variety of lengths and diameters, stability after
sterilization processes, and ease storage are all essential details to obtain a valuable
commercial vascular substitute. Government regulations must be considered during all
the process. All these parameters were contemplated in this project.
1.7 Thesis outline
The purpose of this thesis was to obtain the prototype of a small caliber vascu-
lar prothesis for its application in damaged vascular tissue substitution. For the in
vitro performance experiments, specific reactor has been designed, these are meant to
recreate physiologically relevant environment condition, optimal for these tests. The
characterization will be performed in vitro, for both mechanical and biological tests,
and the in vivo experiments are also presently running. When significant results will
be reached the preclinical trial of the product will be complete.
Concerning the industrialization part, an economic estimation will be presented
in the BP, this will allow to confirm the availability of the project. Moreover, the
pre-engineering of the industrial production reactor, which is based on experimental
design parameters, will guarantee the performances of the prototype characterized in
the laboratory.
The future perspectives concern the in vivo study of the scaffold. The possibility
to use the same crosslink technique, increasing the crosslinking agent concentration in
the final treatment step, was also evaluated. The goal of this protocol variant is to
modify the mechanical properties of the scaffold in order to have a possible application
as an arteriovenous fistula in hemodialysis treatment.
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2 Materials and methods
2.1 Decellularization process
Porcine femoral and carotid arteries, provided by Life and Device S.r.l. (Turin,
Italy), have been decellularized with a three-step protocol. In summary, the vessels
have been treated with a 1 M NaCl, 0,8 mM CHAPS and 2,5 mM EDTA solution for
1 hour at 37 ◦C under stirring. After prolonged PBS rinsing, the matrices have been
treated with a second solution of 1 M NaCl, 18 mM SDS and 2,5 mM EDTA for 1
hour at 37 ◦C under stirring. Finally, in order to completely remove the residual DNA
content, samples have been treated with a solution of 6,4 µM Deoxyribonuclease I from
bovine pancreas (Sigma-Aldrich, USA), 0,1 M MgCl2, and 0,9 M NaCl, and stirred for
16 h at room temperature. The decellularized vessels have been stored at –20 ◦C before
use.
2.1.1 Functionalization of the decellularized biologic tissue (sueGraft®
process)
Decellularized matrices have been enriched with 1 mg/ml polylysine (Sigma-Aldrich,
USA). The process (sueGraft®) used was optimized by TissueGraft S.r.l., all details
are owned by the company.




3. Polylysine grafting: decellularized matrix subjected to the enrichment process
2.1.2 Evaluation of the decellularization procedure
In order to verify the efficiency of the decellularization process, several analyses were
performed (Wolf et al. 2012), including histology to evaluate the absence of cellular ma-
terial using 4’, 6’-diamidino-2-phenylindole dihydrochloride (DAPI) and hematoxylin
and eosin (H&E) staining. For the nuclear staining analysis (DAPI), samples were
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fixed in a 4% formaldehyde solution, then rinsed in PBS and soaked in DAPI solution
(300 nM for 2 minutes). After an additional PBS rinsing, samples were observed under
a fluorescence microscope.
For H&E staining, samples were fixed in 4% formaldehyde solution, dehydrated and
paraffin embedded. Samples were then cut into sections of 5 µm, rehydrated and soaked
in hematoxylin for 15 minutes. Following this, eosin solution (0,05% eosin in distilled
water and acetic acid) was applied for 1 minute. Finally, samples were dehydrated
and observed with an optic microscope (Leica DM2500, Leica, Germany). Samples
images have been acquired through a Leica DFC7000 T camera (Leica, Germany) and
analyzed with Leica Application Suite X software (Leica, Germany).
In addition, the amount of DNA in each sample was also quantified through a DNA
quantification assay. Native and decellularized vessel slices (5x5 mm) were lyophilized
and digested for 16 h at 55 ◦C in a buffer solution, containing 100 µg/ml proteinase
K, 75 mM NaCl, 25 mM EDTA, 1% SDS, pH=8. Samples were incubated with a 6
M NaCl solution for 30 minutes and centrifuged at 15.000 rpm; followed by 1 mL of
isopropanol. In order to precipitate the DNA after centrifugation, the supernatant was
removed, and 70% ethanol added. After evaporation of ethanol, 20 µL of ultrapure
water was added and the amount of DNA measured with full-spectrum UV-visible
measurements (NanoDrop 2000, Thermo Fisher Scientific, USA).
Finally, agarose gel electrophoresis was used to visualize the DNA fragmentation.
Briefly, 50 ng of DNA from native and decellularized samples were mixed with EZ-
Vision loading buffer (VWR, Italy), and loaded on a 1% agarose gel. After the elec-
trophoresis, DNA was visualized with ChemiDoc Imaging System (BioRad, Italy).
2.2 Enrichment process assessment and morphological analy-
sis
2.2.1 X-ray Photoelectron Spectroscopy (XPS)
XPS analysis was conducted with a Perkin Elmer PHI 5600 ESCA system. The
instrument is supplied with a dual Al (monochromatic) and Mg anode operating at 10
kV and 200 W. The diameter of the analyzed spot was about 500 µm, the sampling
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depth was 5–8 nm, and the base pressure 10–8 Pa. The angle between the electron
analyzer and the sample surface was 45 degrees.
After preliminary evaluation using the monochromated X-ray source, spectra were
acquired using the non-monochromated Mg anode, given side-effects due to charging
were much lower. Analysis was conducted acquiring wide range survey spectra (0 to
1.000 eV binding energy) and detailed high-resolution peaks of relevant elements.
Quantification of elements was completed using the software and sensitivity factors
furnished by the manufacturer.
2.2.2 Attenuated Total Reflectance Infra-red spectroscopy (ATR-IR)
ATR-IR spectra were obtained using a Nicolet iS10 ATR-IR spectrometer with a
diamond crystal (Thermo Fisher Scientific, USA). Samples were placed on the crys-
tal and held steady by the specific crimping tool. The experimental set up involved
acquisition of 32 scans in the range 500–4.000 cm–1, both of sample and background,
at a resolution of 4 cm–1 with the sampling depth is approximately 1, 6 µm. Beside
decellularized and polylysine-enriched samples, the ATR-IR spectrum of polylysine
(Sigma-Aldrich, USA) was acquired as a reference.
2.2.3 Confocal microscopy
The microscopy visualization of the structures was completed using a Leica TCS
SP8 DLS (Digital LightSheet, CLF, Harwell, UK) system with image acquisition tech-
nical information as shown in Table 10. The focus of this tool was the observation of
the scaffold collagen structures under static conditions. Samples were not stained but
fixed in situ with agar to immobilize the sample during the test.
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A B C D
Field of view
1471, 52 µm x
1471, 52 µm
1471, 52 µm x
1471, 52 µm
735, 76 µm x
735, 76 µm









of 1, 5 µm
342 steps spaced
of 1, 5 µm
Illumination laser 405 nm 405 nm 405 nm 405 nm
Laser power 25 µW 25 µW 25 µW 25 µW
Exposure time
per plane
600 ms 600 ms 300 ms 600 ms
Bandpass detection
filter













for light sheet creation







Table 10: Technical data of confocal images.
2.2.4 Micro Computed Tomography (Micro-CT)
A micro-CT system (High Flux Nikon XTEK Bay, Manchester X-ray Imaging Fa-
cility (MXIF) was used to non-destructively image and visualize the three-dimensional
micro-morphology as previously described (Disney et al. 2017; Metscher 2009). Stain-
ing method used was 1% (w/v) phosphotungstic acid, H3PW12O40 (PTA) in water for
40 h followed by washing in 70% ethanol and dried for 48 h at room temperature.
Samples were mounted on a stage within the imaging system and subsequently
scanned at a voltage of 100 kV and a current of 50–100 mA. Specimens were scanned
at a 2 µm resolution with an integration time of 1.000–1.400 ms to produce 3D images.
Raw 2D images were thresholded to remove background values (threshold value = 60)





Mechanical properties of native and decellularized enriched matrices were tested.
The Young’s modulus and tensile strength of the different samples was measured,
briefly, Young’s moduli were quantified from the stress-strain curve obtained with the
Instron 5564 (Instron Corporation, Massachusetts USA). System control and data anal-
yses were performed using Instron® Bluehill™ 3 material-testing software (Instron Cor-
poration, Massachusetts USA). Sample dimensions (length, width and thickness) were
measured in order to normalize the mechanical test parameters. Uniaxial tests were
performed at room temperature and with a tension rate of 0,5 mm/s.
Burst pressure was also measured. The test was performed using a hydraulic press,
a high-precision digital pressure gauge and a PBS solution as a liquid. The sample was
stressed by pushing the PBS until bursting, thus detecting the maximum operating
pressure in laboratory conditions.
Mechanical properties were also evaluated after simulation of physiological con-
ditions (dynamic condition test). Decellularized and polylysine-enriched vessels have
been inserted in a circuit, composed of a peristaltic pump (Masterflex L/S, Cole-Parmer
instrument Company, USA), 10 mm diameter tubing (Cole-Parmer instrument Com-
pany, USA), and a chamber containing the samples and filled with the PBS. Fluid speed
was 15 mL/min and samples were tested for up to 30 days. Samples were weighed be-
fore and after the dynamic test in order to evaluate the samples’ weight loss after
dynamic conditions were applied. Finally, both Instron and burst pressure tests, were
performed after dynamic conditions.
2.4 Cell viability assay
Cell viability of human umbilical vein endothelial cells EA.hy926 (ATCC® CRL-
2922™), cultured on decellularized and enriched matrices, was assessed. Cells were
cultured with Dulbecco’s Modified Eagle’s Medium (DMEM – Euroclone, Italy) en-
riched with 10% fetal bovine serum (FBS), 2 mM glutamine and 100 U/mL penicillin
(Euroclone, Italy). Endothelial cells were cultured at 5 · 104 cells/cm2. In order to
evaluate cell viability, after 1, 3, and 7 days of culture, a MTS assay (CellTiter 96®
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AQueous Non-Radioactive Cell Proliferation Assay, Promega, Italy) was performed.
Briefly, a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium solution was added to each sample for 3 h. Absorbance was measured
by UV-VIS spectrophotometry (V-630 UV-Vis Spectrophotometer, Jasco, USA), at a
wavelength of 490 nm. Measures were proportional to cell viability.
In order to evaluate cell adhesion and proliferation, EA.hy926 cells were cultured
on decellularized and polylysine enriched matrices for 3 and 7 days. Matrices were
then observed through Hematoxylin-eosin staining, as described in Section 2.1.2.
Cell adhesion was evaluated after simulation of physiological conditions (dynamic
condition test). In this purpose, a bioreactor was designed and printed in 3D to re-
produce conditions as similar as possible to physiological ones, like gravity force and
temperature.
EA.hy926 were cultured on the lumen side of decellularized and polylysine-enriched
vessels for 24 hours. Afterwards, samples were inserted in a circuit, composed of a
peristaltic pump (Masterflex L/S, Cole-Parmer instrument Company, USA), 10 mm
diameter tubing (Cole-Parmer instrument Company, USA), and fixed to the bioreac-
tor’s structure. The bioreactor allows to create an external and internal flow in the
vessel. In this case the external circuit didn’t have a flow whereas, the internal vessel’s
flow was 15 mL/min. The fluid filled was DMEM enriched with 10% FBS and samples
were tested for up to 3 days.
2.5 Haemocompatibility
Thromboelastography (TEG) is a technique that measures several parameters rel-
ative to blood coagulation by evaluating the viscoelastic properties of blood from the
beginning of coagulation to the clot rupture with fibrinolysis. Particularly impor-
tant parameters are the coagulation formation, its progression, maximum strength,
and stability, which provides important information on coagulation, fibrinolysis, and
platelet functionality. Blood samples were collected in Vacutainer (BD, USA) con-
taining sodium citrate and tested at 37 ◦C. Blood was exposed to the control graft
(Dacron®), the decellularized scaffold and the enriched scaffold for 30 minutes and sub-
sequently analyzed using Thromboelastograph® (TEG® 5000 Thrombelastograph®
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Hemostasis Analyzer System) and the Kaolin TEG standard protocol. Briefly, after
30 minutes 1 mL of blood was collected and placed in a vial containing kaolin. After
few seconds, 340 µL of blood were sampled in the thrombelastograph with 20 µL of
calcium chloride, in order to eliminate the anticoagulant effect of sodium citrate. Co-
agulation parameters were evaluated through thromboelastogram obtained at the end
of the testing time.
2.6 Industrialization
According to the “Manual on Economic Development Projects” from the United
Nations Economic Commission, there are several aspects to consider from the economic
point of view in order to create the feasibility study of the plant, in particular the com-
pilation of the study market, analysis of the current demand, projection and elasticity
of demand, and product price estimation are the main features.
This document also evaluates the basic aspects of the project engineering, such as
selection of the production process, specification of operating and assembly equipment,
buildings and site and plant layout, supplementary equipment, flexibility of productive
capability, work of schedules among others (Nations 1958).
The industrialization part developed for this project is a simplified part of the
documents necessary for phase I of the project. It is composed of an economical part,
which contains a BP, aiming to make a first assessment on the project feasibility, and
an engineering part. In the latter part the installation core’s design, which is the
production reactor, has been performed in order to guarantee the same performances
of the laboratory’s prototype. Given the type of production process, it was considered
necessary to include a table of the reactor’s operation cycles.
2.6.1 Business plan
The business plan is part of the feasibility study, which is important to preview and
guarantee the success of the project’s industrial implementation.
The plant’s capacity estimation comes from the document “Vascular Grafts Market
2019 Industry Demand, Share, Global Trend, Industry News, Business Growth, Top
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Key Players Update, Business Statistics and Research Methodology by Forecast to
2025” published by the company The Express Wire on May 2019 (Wire 2019).
Capital expenditures (CAPEX) includes the CE certification amount, comprising
the preclinical and clinical trials, has been considered in the plant costs. The plant’s
construction total cost is based on the following assumptions. The production plant
has been inserted in an already existent production plant launching a new product
line. This allows to lower the staff’s costs, since some workers can be shared with the
already existing installation. In the same way, the aseptic environment production area
will also be shared.
The implant can be realized in any EU country, since the legal aspects considered
allow to obtain the CE certification and therefore the commercialization of the medical
devices in the EU. Moreover, the economical parameters that were fixed to make an
economic estimate are based on the Italian legislation, since the product was developed
in Italy.
Operating expenses (OPEX) includes the production costs in terms of chemicals,
electricity and wastewater production, derived from a balance of materials and energy
of the plant.
In the BP the different financial parameters usually used in this kind of studies,
like inflation rate, interest rate, and spread were considered over the operative duration
time of the plant, which is 10 years.
The taxes considered to obtain the Net Cash Flow were applied in terms of the
Italian legislation: Imposta sul reddito delle società (IRES), Imposta regionale sulle
attività produttive (IRAP) and imposta municipale unica (IMU).
2.6.2 Reactor design
In order to obtain the design parameters of the reactor some experiments have
been performed. The standard batch decellularization protocol used during the arterial
scaffold prototype obtainment was taken as a reference, to establish a protocol suitable
to produce the same product but on a larger scale.
The important parameters to determine are, not only the volume of liquid in con-
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tact to the tissue, but also the different flow inside and outside the vessel. With this
purpose a commercial bioreactor was used. To evaluate the efficacy of the different
flows of the decellularization solution, cells removal through Hematoxylin-Eosin stain-
ing was analyzed. Once the volume to weight ratio has been fixed, a 30% increase was
considered as a security factor in the reactor’s design.
The paraments obtained were combined to fluid dynamics’ basic principles related
with adimensional numbers for scale the process. Specifically, for Reyonolds (Re) num-
ber, a test was performed using a commercial reactor showed in Figure 6 (MiniBreath®)
in order to determine the optimal flow for each phase of the treatment. The duration
and flow have been optimized for each phase, which fixed the adequate conditions for
mass transport phenomenon in the system, with the aim to optimize the process and
preserve the material.
Figure 6: MiniBreath® commercial bioreactor.
The hydraulic circuit configuration is divided in two different circuits, one of them
allows only vessel perfusion, while the second one feeds the solutions inside the culture
chamber. In the inner path, the solution is drawn from an external reservoir thanks
to a Harvard MPII® mini-peristaltic pump (Harvard Apparatus), it flows inside the
MiniBreath® using a Pharmed BTP tubes, 1/16’ (1,6 mm) ID, and then into the vessel
before it goes back into the reservoir. In the outer path the action of a MasterFlex
L/S® (Cole Parmer Instrumental Company) pump moves the fluid from the reservoir
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to the culture chamber and back into the common reservoir using a Pharmed BTP
tubes, 1/8’ (3,2 mm) ID.
In this way, each process phase has a different flow rate to modify the Re number
and consequently inertial force compared with the viscous one, in order to obtain an
efficient treatment across the sample’s wall thickness. Maximum inlet flow rate has
been fixed using the physiological value to avoid the tissue damage, in this case the
flow rate considered using a human popliteal artery, due to its similar characteristics,
is 67 mL/min (Holland et al. 1998).
Removing the chemical residues is a very important aspect, due to the immuno-
genic response they may cause (Struecker et al. 2017), therefore, the reactor’s design
and production phases must be carefully evaluated, and the washing phase must be
standardized and controlled. In this purpose, diffusion phenomenon is predominant in
the washing steps in order to guarantee the complete removal of the detergent.
Re number represents the relationship between inertial and viscus forces. Focusing
on the flow of the fluid inside a circular section pipe, at low Re (≤ 1.000) the viscus
effects dominate, and the flow is laminar. At high Re (≥ 2.000), inertial forces govern
the flow dynamic, which becomes turbulent.
Regarding the external circuit, some approximations have been made to calculate
Re. Since the reactor chamber has a squared cross section it was approximated to a
circular one. In this way, the configuration can be described as the flow of solution
inside the annulus given by two coaxial cylinders. The chamber Re was calculated
using the hydraulic diameter approximation due to the flow not flowing in a circular
pipe.
The largescale production reactor was designed considering all the parameters ob-
tained with the MiniBreath®. All the measures and dispositions of the different parts
of the reactor will be specified in the attached design belonging to Chapter 3.6.2.
2.7 Ethics
Life and Device company was charged of both providing the porcine native arteries
and of performing the in vivo studies which are running at the moment. This company
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guarantees the compliance of the Directive 2010/63/EU of the European Parliament
and of the Council of September, 22th, 2010 and the Decreto Legislativo March, 4th,




3.1 Decellularization process efficiency
In order to evaluate the efficiency of the decellularization protocol, DAPI stain-
ing was performed on native and decellularized tissue. Figure 7 shows the native
tissue and the presence of cellular nuclei in native tissues while, after the decellulariza-
tion treatment, however, no nuclei were present. H&E histology results confirmed the
preservation of the ECM microstructure within the decellularized samples. No cellular
nuclei could be detected in the decellularized tissue samples.
DNA quantification on native and decellularized tissues strengthened the previous
results, indicating a successful DNA removal from the matrix. In contrast to native
tissue, which contained 860 ± 300 ng DNA per mg wet weight (n = 3), decellularized
tissues showed a significant decrease of DNA content to 15 ± 11 ng DNA per mg wet
weight (n = 3). Agarose gel showed that no DNA strands longer than 100 bp were
available on decellularized samples, while in native samples the DNA presence was
verified.
Figure 7: Decellularization of porcine artery showing A) DAPI and H&E histology
before and after decellularization process. B) Quantitative determination of DNA in a
native and decellularized matrix. Data are expressed as mean values ± SD. (n = 3,
∗ = p ≤ 0, 05). C) Agarose gel electrophoresis of DNA derived from native and
decellularized matrices. The image is representative of three different analyses.
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3.2 Enrichment process assesment and morphological analysis
Samples were analyzed, as shown in Figure 8 A and B, the survey spectra of decel-
lularized and polylysine-enriched samples show differences, with the obtained surface
composition reported in Table 11. Decellularized scaffolds showed peaks due to car-
bon, oxygen and silicon, and just a very weak signal from nitrogen. XPS tests just
the outermost molecular layers of materials (the sampling depth is about 5–8 nm),
and the obtained data likely reflects surface side-effects due to processing. Silicone is
a common contaminant of surfaces and the peak of Si is a common finding in surface
analysis of biological samples. There was also a lower than expected N/C and N/O ra-
tio, which was probably due to processing aids (see also discussion of ATR-IR results)
remaining on or combined with the sample surface. In contrast, the XPS spectrum of
polylysine-enriched samples showed a strong peak due to nitrogen. Hence, the sample
surface showed being enriched with a nitrogen-containing compound, clearly support-
ing the presence of polylysine. Further information was provided by ATR-IR analysis,
as reported in the next section.
Sample O N C Si
Decellularized 17, 1± 0, 3 1, 4± 0, 1 68, 4± 0, 3 13, 1± 0, 5
Polylisine 16, 7± 0, 2 11, 3± 0, 4 72, 0± 0, 4 −
Table 11: Surface composition (atomic %) of tested samples (n = 3).
ATR-IR analysis of decellularized (red), polylysine-enriched (blue) and reference
polylysine (green) was analyzed in the amide band region of the IR spectrum (Figure
8 C). The sampling depth of ATR-IR, using a diamond crystal, is around 1,6 µm,
that is this technique is less surface-sensitive than XPS. All samples show the typical
spectral features due to amide bonds, as expected. Concerning differences between
tested samples, the Amide II band at about 1.550 cm–1 shifts towards lower wavenum-
bers from decellularized to polylysine-enriched (arrow), centering close to the Amide
II band of the polylysine reference. Also, around 1.400 cm–1 the shape of the band
(arrow) changes from decellularized to polylysine. Taken together, XPS and ATR-IR
results strongly suggest that successful enrichment with polylysine of the decellularized
sample is obtained through this process.
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Figure 8: XPS spectra of A) decellularized and B) polylysine enriched matrices. C) AT-
IR spectra of decellularized (red), polylysine enriched matrices (blue) and Polylysine
as a control (green).
In Figure 9 A the structure of decellularized and polylysine-enriched matrices are
shown through confocal microscopy. The polylysine-enriched sample shows a structure
of fractures better defined than in the decellularized sample, and the roughness is nar-
rower than the latter. In general, the enriched sample shows more vertical oriented
fractures, while in decellularized the lines are not so straight composing soft curves.
The images suggest that the enrichment treatment changes the micro and macro col-
lagen structure, orientating and bridging collagen fibers, as can be seen in Figure 9
B, which confirms the data obtained from confocal microscopy. Indeed, decellularized
sample’s tissue seems thinner and hollower with respect to both native and polyly-
sine enriched matrix. The thickness and the wall microfiber structure of polylysine
enriched matrix seems adequately similar, suggesting that the fiber reorganizing after
enrichment process leads to a structure comparable to native sample.
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Figure 9: A) Confocal microscopy of decellularized and polylysine-enriched vessels. B)
Micro-CT analysis of native vessel, decellularized and polylysine-enriched matrices.
3.3 Mechanical test
3.3.1 Young’s modulus, tensile strength and burst pressure results: static
conditions
To characterize the mechanical properties (Figure 10 A and B) specimens were
tested, using an Instron instrument, and strained until specimen failure.
The Young’s modulus is directly related to the compliance of the material. Decel-
lularized samples present a significant Young’s modulus decrease when compared with
native and polylysine sample values. On the other hand, the tensile strength of the
polylysine enriched matrix is increased, compared to the native vessel, while the same
parameter between the decellularized matrix is lower with respect to the other samples.
The figure shows that, with respect to the native control, elasticity is not affected.
The Young’s modulus of the enriched matrix is shown to be not significantly different
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to the native vessel. The scaffold wall is strengthened after enrichment.
3.3.2 Young’s modulus, tensile strength and burst pressure results: dy-
namic conditions
Samples were tested for up to 30 days under dynamic flow conditions, perfusing
the vessel lumen. After performing dynamic tests, matrix degradation was measured.
All the samples reveal a weight loss: native samples’ mass decreases of 60%, while
decellularized samples roughly 55%. Nevertheless, the polylysine samples present only
a 28% weight loss, with an evident matrix preservation compared to other samples
(Figure 10 C).
Burst pressure was measured before and after applying dynamic conditions. Native
artery pressure is 1,3 bar, while with polylysine treatment, the value is considerably
increased, rising to 3,2 bar.
After 30 days, the maximum pressure value supported by the samples decreases by
40% in the native sample and only a 13% in the sample treated with polylysine.
The successful performances of polylysine enriched matrices are confirmed by the
evaluation of matrix degradation in terms of tensile strength loss. Indeed, after 10 days
polylysine enriched matrices lose only 5% of tensile strength while, decellularized matrix
is 17% weaker than the static control. The differences are more evident after 20 days
where decellularized matrices lose 26% of tensile strength, while treated decellularized
vessels showed similar performances with respect to 10 day samples.
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Figure 10: Mechanical testing results under static conditions: (A, left panel) Young’s
modulus and tensile strength representation for native, decellularized and polylysine
grafting. Data are expressed normalized with a native vessel. The data origin is the
stress–strain curves. Data are expressed as mean values ± SD. (n = 3, ∗ = p ≤
0, 05). B) Burst pressure data for native, decellularized and polylysine grafting. Data
are expressed as mean values ± SD. (n = 3, ∗ = p ≤ 0, 05). Mechanical testing
results under dynamic conditions: C) Burst pressure data for native, decellularized,
and polylysine grafting for static and dynamic conditions. Data are expressed as mean
values ± SD. (n = 3, ∗ = p ≤ 0, 05). D) Degradation assays in terms of weight loss.
Data are expressed as mean values± SD. (n = 3, ∗ = p ≤ 0, 05). E) Degradation
assays in terms of tensile strength loss. Data are expressed as mean values ± SD.
(n = 3, ∗ = p ≤ 0, 05).
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3.4 Cell viability assay: static and dynamic conditions
Endothelial cells were seeded in the vessels lumen and cell proliferation rate was
measured after 1, 3 and 7 days. Figure 12 A shows comparable cell proliferation
rates for decellularized and polylysine-enriched samples after 7 days. Endothelial cells’
adhesion and proliferation were also evaluated, using hematoxylin-eosin and DAPI
staining. Results show that after 3 days, cells adhered on both decellularized and
polylysine-enriched samples, while after 7 days of culture cells formed an almost con-
tinuous monolayer only on polylysine-enriched surfaces (Figure 12 B). Finally, cell
adhesion was evaluated after 3 days of dynamic conditions. In this purpose, as showed
in Figure 11, a bioreactor was designed and printed in 3D.
Figure 11: Photographs of the 3D printed bioreactor.
In Appendix A, sections and 3D pictures are reported.
In Figure 12 C DAPI staining shows almost no cell nuclei on decellularized sam-
ples, indicating that cells do not remain adherent to the matrix. On the other hand,
polylysine-enriched samples show cell nuclei almost forming a continuous monolayer




Figure 12: A) Endothelial cells viability assays. MTS test was performed after 1,
3, and 7 days. Data are expressed as mean values ± SD. (n = 3, ∗ = p ≤ 0, 05).
B) Hematoxylin-Eosin staining of decellularized and polylysine enriched matrices with
cells cultured for 3 and 7 days. C) DAPI staining of decellularized and polylysine




The material’s haemocompatibility was evaluated using thromboelastography (TEG).
Among the coagulation parameters, reaction time (R) indicates the time required to
induce the clot formation. The matrices treated with polylysine have a significantly
increased R-value with respect to Dacron® and decellularized matrices. Fibrinogenic
activity is rather decreased on enriched matrices, as a result the clot strength is lower
than both matrices used as reference. The coagulation time parameter is directly cor-
related with the required time for the clot formation, in order to reach the maximum
strength value before starting the dissolution process. This value increases in the sam-
ples treated with polylysine reflecting a benefit in terms of functionality. In addition,
platelet aggregation confirms the lower rate in the clot formation process (Figure 13).
These results clearly indicate a favorable influence on coagulation parameters in the
presence of polylysine enrichment in terms of haemocompatibility.
Figure 13: Haemocompatibility test. Coagulation parameters (A: reaction time; B:
coagulation time; C: platelet aggregation; D: fibrinogenic activity) were evaluated on
synthetic vascular substitutes (Dacron®) and treated matrices. Data are expressed as





The plant’s capacity was fixed in 50.000 vessels each year, although the market
study consulted estimates the European market close to 600.000 vessels each year.
This consideration allows to approach the investment in a conservative way and allows
to take it as a constant during all the period with a low risk.
In order to fix the product price, similar competitor’s prices were consulted and, as
an average price, 1.500 e was obtained for each vessel prosthesis. To take a position as
an aggressive competitor in the market, the sell product price was fixed in 800 e/vessel.
Considering the price and the amount of product the total revenue is 40 Me each
year which will be actualized using an inflation rate during the 10 years of the business
plan period.
Total operating cost considered includes raw materials, chemicals, quality control
and routine analysis, maintenances, administration and finance cost, work staff, electri-
cal energy, insurance, delivery, wastewater treatment, amortization, and contingency.
In the Appendix B all the costs are summarized. Among them, the heist cost corre-
sponding to raw materials and chemicals. Femoral and carotid arteries are used as a
raw material and the cost was fixed in 1.000 e including the animal and extraction cost.
Chemicals cost is an incisive cost in the business plan due to DNase and polylysine
have a 5.290 e/g and 2.540 e/g respectively.
Sales have been considered constant throughout the business plan period to simplify
the estimate and due to the lack of predictive tools at the moment. This consideration
is motivated by two aspects, the first concern that the vessel prosthesis production
line is integrated into an existing plant operating into the medical devices field. This
will allow to benefit from the distribution network and contacts already used by the
company. Secondly, the production capacity considered is around the 10% of the total
market demand so, although some occasionally fluctuations in sales occur, on average
all production will be absorbed by the market. As a result of these two considerations




OPEX, CAPEX, taxes and its amounts are summarized in Appendix B as well as
the equity and the financed amount for the investment.
As a result of the business plan study internal rate of return (IRR) and return of
the investment (ROI) indicators were obtained. They confirm the economic viability
of the investment at this phase of the project.
3.6.2 Reactor design
Different tests were performed to obtain the ratio volume of solution to length of
vessel treated. Figure 14 summarizes decellularization protocol for the first, second
and third experiment and its H&E staining histology. From these three results it
is important to underline the material’s behavior, because constant flows inside and
outside cannot guarantee the vessel’s decellularization.
Figure 14: Hydraulic conditions and their H&E staining results for the three different
settings of the dynamic decellularization test.
Flow parameters reported on Table 12, obtained the best performance in terms of
decellularization, volume and time consuming. Figure 15 shows the matrix preservation
and the absence of cell’s nuclei.
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Qin Rein Qout Reout Time
(ml/min) (ml/min) (h)
Phase 1 7 107 48 107 1
1st PBS wash 9 133 60 134 0,5
2nd PBS wash 2 32 15 33 1
3rd PBS wash 5 83 37 83 1
Phase 2 7 107 48 107 1
1st PBS wash 9 133 60 134 0,5
2nd PBS wash 2 32 15 33 1
3rd PBS wash 5 83 37 83 1
Phase 3 4 59 25 107 15
Wash in H2O 7 107 48 107 2
Table 12: Final decellularization protocol selected for the three treating and washing
phases. For each inner and outer solution are reported volumetric flow rates, Re and
time.
Figure 15: H&E histology of the blood vessel obtained using the selected protocol.
Re number representation during the time (Figure 16) reflects the intervention of
the inertial forces compared to the viscous forces during the first steps of washing
due to the high flow. Instead, an opposite situation occurs by significantly decreasing
the flow, as in the second washing phase, in which the action of the viscous forces
is stronger. Concerning the final washing step, an intermediate flow rate has been
stablished, between the previous two, thus balancing the action of inertial and viscous
forces. Finally, regarding the 3st step solution, an even smaller flow rate has been




Figure 16: Schematic representation of Re for the inner (Rein) and outer (Reout) per-
fusion circuits over time on the optimized MiniBreath® protocol.
According with the 3 ml/cm of treated vessel and the fixed plant capacity, it is
necessary to use 4 reactors.
The design of the production reactor is of cylindrical shape with 23 L of vol-
ume.Internally, it contains a structure formed by 265 hollow tubes of 2 mm of external
diameter and 1,5 mm of internal diameter, which will be introduced in the native ves-
sel. These tubes have perforations of 0,25 mm diameter following a helicoidal path,
with an 5◦ angle in respect to the longitudinal axis, in order to facilitate the fluids’
movement. The space around each tube guarantees the material to be in contact with
the right solution volume.
The fluid will be forced to move inside and outside the vessel with opposite flow
direction, which increases the effectiveness of the material’s treatment. Because of
this, the reactor will have perforations on the external chamber’s base, which will be
connected to tubes and controlled by automatic valves which fix the fluid’s flow in the
filling, emptying and recirculation phase.
Given the dimensions and configuration of the tubes that make up the reactor, the
most suitable material for its realization is steel. This implies that the rest of the reactor
must be constructed in ANSI 316 steel, in order to weld the parts to the structure and
to avoid weak points in the structure, that would be created using other materials such
as the plexiglass. The welds used in its construction phase must be as flat as possible,
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to minimize undesirable material deposition. Seal welds are important to guarantee
the sterility of the process even though the environment will be controlled. The costs
of the material and the construction of the reactor have been considered acceptable
within the BP study.




Although autologous arterial and venous grafts are the gold standard as bypass graft
material, they are not available in roughly 40% of patients, due to their insufficient
length or quality of native vessels (Moroni and Mirabella 2014).
Synthetic grafts, including Dacron® and ePTFE, which efficiently work for large-
diameter vascular grafts, have shown disappointing clinical results in small-diameter
artery reconstruction, due to thrombotic complications, when compared to venous
bypasses (Klinkert et al. 2004). For these reasons, decellularized scaffolds were intro-
duced. The ECM is an optimal substrate in terms of biological performances, because
it is able to drive cell adhesion, proliferation, and differentiation (Barnes et al. 2011); in
this way, unlike synthetic materials, decellularized substitutes are able to solve a prob-
lem as complex as the repopulation with different cell types, as showed by Pellegata
et al. (2013). On the other hand, decellularized matrices progressively lose the suitable
mechanical properties needed for tissue replacement (Williams et al. 2009; Xiong et al.
2013). In the present study, we exploited the properties of the decellularized matrices,
strengthened with polylysine enrichment, to prevent wall weakening (Gu et al. 2018).
Polylysine is a polymer that has been widely used in tissue engineering, as a promoter
of cell adhesion, because of its strong positive charge (Wang et al. 2018; Zhang et al.
2019) and as a biomaterial strengthener (Collin et al. 2004; Wang et al. 2016).
The evaluation on the effectiveness of the decellularization process showed that
no cell nuclei are present in decellularized matrices, and that the DNA quantity is
significantly lower than the native vessel, as well as also being lower than the gold
standard defined by literature (Crapo et al. 2011). However, it is unclear if the DNA
left in decellularized matrices could elicit a biological response from the host (Keane
et al. 2012). Several commercial products derived from decellularized matrices with
positive clinical outcomes contain DNA fragments, for this reason the probability that
residual DNA could induce a host response is low (Gu et al. 2018; Pellegata et al. 2013).
In order to predict the possible outcome of a vascular substitution, mechanical
properties are a crucial parameter to evaluate. In particular, graft failure occurs when
the substitute’s compliance is different from the native vessel (Xue and Greisler 2003).
Although Young’s modulus and failure strength of these substitutes are not signifi-
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cantly different from native vessels, the compliance was not taken into account as a
key factor (Bergmeister et al. 2005; Ketchedjian et al. 2005; Mahara et al. 2015). On
the contrary, Xue and Greisler (2003) showed that, in human patients graft failure
occurs when the substitute’s compliance is different from the native vessel. For this
reason, in this study the differences in compliance between polylysine-enriched substi-
tute and the native vessel were evaluated. As known from literature, compliance is also
related to wall stiffness (Baltgaile 2012), which can be evaluated by Young’s modulus.
Mechanical characterization of the matrices in static conditions showed that polylysine
enriched matrix showed increased wall strength, while the Young’s modulus is similar
to that of native vessels. The assessment of mechanical properties shows that, given
the similarities in stiffness between native vessel and polylysine enriched matrices, the
compliance is comparable.
In order to assess the durability of the enrichment and the behavior of the substi-
tute under dynamic conditions, degradation rates were also evaluated, as weight loss
and tensile strength loss. In both cases, polylysine enriched vessels showed the best
behavior, retaining matrix and mechanical properties, while all the other matrices con-
sidered lost their properties after 30 days. The importance of mechanical properties
evaluation is underlined in Williams et al. (2009), who studied the differences in stiff-
ness between fresh and decellularized rabbit carotid arteries; also Mahara et al. (2015)
focused on difference in the stress strain curve between original tissue and peptide-
enriched decellularized ostrich carotid artery graft; finally, López-Ruiz et al. (2017)
evaluated tensile strength, maximum load and burst pressure of native, decellularized
and coated porcine carotid arteries.
Treated matrix cytocompatibility showed to be adequate compared to decellular-
ized matrices, indicating a favorable environment for efficient repopulation by the host’s
vascular cells. The adequacy of modified decellularized matrices was also demonstrated
by Mahara et al. (2015) who indicated adequate cell repopulation of peptide-enriched
decellularized grafts in porcine model; also Boerboom et al. (2002) confirmed good
recellularization of a decellularized carotid artery implant; finally Hilbert et al. (2004)
further highlights successful repopulation of decellularized carotid goat graft. More-
over, haemocompatibility tests displayed that polylysine enriched matrices develop
blood clots slower and with less strength with respect to both decellularized matrices
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and Dacron®, a synthetic polymer widely used in vascular substitution. Further-
more, coagulation assays indicate that polylysine enriched matrices could help to avoid
thrombosis, another drawback of synthetic substitute (Fukunishi et al. 2016).
Given the positive results obtained by these in vitro experiments, these polylysine
enriched substitutes are under preclinical evaluation using ovine models.
Overall, our tests confirm the efficiency of both decellularization and enrichment
methods, as well as the ability of polylysine enriched matrices to maintain adequate
mechanical properties, while allowing cell adhesion and proliferation. Thus, the en-
riched biological substitutes could represent an innovative engineering approach for
application in vascular tissue engineering.
Further in vitro studies, using primary endothelial cells and fibroblast, may be
integrated in the scaffold characterization to foresee the scaffold repopulation of all the
cell types that are present in the native tissue.
Vessel prototype’s future perspectives are evolving in two different directions. On
one hand, in vivo test is now carried on using a sheep model (Figure 17) in order to
complete the preclinical phase of this product.
Figure 17: Photograph of the surgical intervention to implant the vascular polylysine
graft in the left carotid artery.
On the other hand, the last grafting step using polylysine presents a promising
approach to obtain a new derivate product, a hemodialysis arteriovenous fistula. This
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new application must be resistant enough to support the frequent puncture necessary
for the hemodialysis treatment. In this purpose, a preliminary test was performed,
different polylysine concentration vessels underwent uniaxial mechanical test in order
to evaluate its Young’s modulus and tensile strength.
Further advances in transversal techniques may be implemented in this vascular
graft. Human-iPSCs decellularised scaffolds could avoid the intake of immunosup-
pressive drugs required after organ transplantation and, in combination with the new
performed amplification cells techniques, the product can be further upgraded. Biore-
actors must be developed from sterility and control point of view to guarantee the
recellularization step. Taken all together, production time and high cost of manufac-
turing must be optimized to implement these new approaches.
From the engineering point of view, the heterogeneity of the raw material is an
aspect to be aware so, extra quality controls can avoid further problems.
Regarding the new traceability requirements stablished in the Directive 98/87/EC,
UDI code must be included for each product in order to be registered in the EU-
DAMED. Implantable decellularization products cannot allow an ink traceability mark
so, a traditional database is the available alternative. New alternatives are already stud-
ied in the food industry field and could be implemented to satisfy the EU requirements
of UDI products (Aung and Chang 2014; Karlsen et al. 2013; Markiewicz-Keszycka
et al. 2019).
Among the available post-sterilization methods, CO2-SC was chosen, since it is
characterized by the mechanical properties’ preservation of the treated material. This
technique offers some versatility by changing the pressure and temperature conditions
during the process, which will offer a different degree of product sterility. These con-
ditions must be established in successive phases of the project. Even so, it has been
considered as a valid alternative, since other companies NovaSterilis or Biobank use
it such as a part of the sterilization process technology in the treatment of human
autologous implants.
The packaging and the stocking of both the raw materials and the final product
must be deepened in successive phases of the project. In this first phase, the stocking
of raw materials is not considered a problem, since it can be frozen at −20 ◦C, it offers
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some flexibility before its use. The distribution of products is usually a problematic
issue in this type of device because the properties of the product can be affected by
environmental changes, which their control can be difficult when it is necessary to
cover large distances or small delivery times. In this case, since the prosthesis will be
produced in Europe and for the European market, it is expected that the distribution
will be carried out by road where the environmental conditions can be easily controlled.
The sensors implementation in the production process control, in addition to in-
creasing the quality and precision of the production, will allow the access to state
economic incentives that currently encourage the implementation of Industry 4.0. A
new generation of sensors, called “Smart Sensors”, allow an easy communication di-
rectly with the user or transferring the data wirelessly (Durresi 2016). The goal of the
Industry 4.0 is not just getting data, but collect data and converting it into useful,
understandable information that optimizes the control of the process and the business
properly. This is the reason why Artificial Intelligence (AI) technologies plays a key role
in the fourth industry revolution, offering a more sophisticated use of machine learn-
ing, digitization, and informed decision making from top to bottom in an organization
(Javaid and Haleem 2019).
Until now, process optimization had been carried out using software such as SixSigma,
AI is revolutionizing the field of industrial processes optimization, because of its very
wide range of applications from process control to logistics, storage, industrial distri-
bution and even plant maintenance prediction.
The benefits of AI implementation in the new industry generation are potentially
huge, thus the designed plant will be equipped with the necessary sensors in order to
obtain the complete control of the important variables for the process involved in the
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Appendix B: Business plan
iii
Appendix B
1. DSCR minimo 29,40 DSCR OK
2. DSCR average 32,61 Coverage not required
Production 50.000 vessel/year Installment -128.573 €
Inflation 1,40%
Turn key 2.000.000 € Ires 24,00%
Other cost 0 € Irap 1,90%
Total investment 2.000.000,0 € IMU 0,20%
Equity 30%
Equity outflow 600.000
Euribor base rate (3 months) 0,30% www.euribor.it/
Spread 4,00%
Interest rate 4,30% Debt 1
Reid of return 10,00% Equity 0
Financial period 180 month 15
0 1 2 3 4 5 6 7 8 9 10
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 Total
Inflation rate 1,00 1,01 1,03 1,04 1,06 1,07 1,09 1,10 1,12 1,13
Vessel production (d=5mm; L=10cm) 50.000                vessel/year 50.000 50.000 50.000 50.000 50.000 50.000 50.000 50.000 50.000 50.000 500.000
Vessel revenue 800 €/vessel € 40.000.000 40.560.000 41.127.840 41.703.630 42.287.481 42.879.505 43.479.818 44.088.536 44.705.775 45.331.656 426.164.241
Revenues € 40.000.000 40.560.000 41.127.840 41.703.630 42.287.481 42.879.505 43.479.818 44.088.536 44.705.775 45.331.656 426.164.241
Raw material 12.500.000 €/year € 12.500.000 12.675.000 12.852.450 13.032.384 13.214.838 13.399.845 13.587.443 13.777.667 13.970.555 14.166.143 133.176.325
Chemicals 20.900.000 €/year € 20.900.000 21.192.600 21.489.296 21.790.147 22.095.209 22.404.542 22.718.205 23.036.260 23.358.768 23.685.790 222.670.816
Quality control & rutine analysis 30.000 €/year € 30.000 30.420 30.846 31.278 31.716 32.160 32.610 33.066 33.529 33.999 319.623
 Maintenance plant 50.000 €/year € 50.000 50.700 51.410 52.130 52.859 53.599 54.350 55.111 55.882 56.665 532.705
Administration & Finance cost 10.000 €/year € 10.000 10.140 10.282 10.426 10.572 10.720 10.870 11.022 11.176 11.333 106.541
Work staff 500.000 €/year € 500.000 507.000 514.098 521.295 528.594 535.994 543.498 551.107 558.822 566.646 5.327.053
Electrical energy 10.000 €/year € 10.000 10.140 10.282 10.426 10.572 10.720 10.870 11.022 11.176 11.333 106.541
Insurance 200.000 €/year € 200.000 202.800 205.639 208.518 211.437 214.398 217.399 220.443 223.529 226.658 2.130.821
Delivery 30.000 €/year € 30.000 30.420 30.846 31.278 31.716 32.160 32.610 33.066 33.529 33.999 319.623
Wastewater treatment (23,907 t/a 18euro/t)) 10.000 €/year € 10.000 10.140 10.282 10.426 10.572 10.720 10.870 11.022 11.176 11.333 106.541
Amortization 5 year € 400.000 400.000 400.000 400.000 400.000 0 0 0 0 0 2.000.000
Contingency 15,0% € 300.000 304.200 308.459 312.777 317.156 321.596 326.099 330.664 335.293 339.987 3.196.232
Total costs 34.240.005 € 34.940.000 35.423.560 35.913.890 36.411.084 36.915.239 37.026.453 37.544.823 38.070.451 38.603.437 39.143.885 369.992.822
Operating Cash Flow € 5.060.000 5.136.440 5.213.950 5.292.545 5.372.241 5.853.052 5.934.995 6.018.085 6.102.338 6.187.771 56.171.419
Installment € (128.573) (128.573) (128.573) (128.573) (128.573) (128.573) (128.573) (128.573) (128.573) (128.573) (1.285.732)
Loan redemption € 0
Revenew € 4.931.427 5.007.867 5.085.377 5.163.972 5.243.668 5.724.479 5.806.422 5.889.512 5.973.765 6.059.198 54.885.687
Ires € 1.183.542 1.201.888 1.220.490 1.239.353 1.258.480 1.373.875 1.393.541 1.413.483 1.433.704 1.454.207 13.172.565
Irap € 93.697 95.149 96.622 98.115 99.630 108.765 110.322 111.901 113.502 115.125 1.042.828
IMU 0,2% 3080 € 3.080 3.080 3.080 3.080 3.080 3.080 3.080 3.080 3.080 3.080 30.800
Net Cash Flow -600.000 3.651.107 3.707.749 3.765.184 3.823.423 3.882.478 4.238.759 4.299.479 4.361.048 4.423.480 4.486.786 40.039.494
Cumulated Cash Flow -600.000 3.051.107 6.758.857 10.524.041 14.347.464 18.229.942 22.468.702 26.768.180 31.129.229 35.552.709 40.039.494
DSCR 29,40 29,84 30,28 30,74 31,20 33,97 34,44 34,92 35,40 35,90
3. NPV € 21.703.387
4. IRR 610,07%
5. ROI 1st year 253,00%
6. ROE 1st year 608,52%
1. DSCR min: Min Debt Service Coverage Ratio
2. DSCR average: average Debt Service Coverage Ratio
3. NPV: Net Present Value
4. IRR: Internal Rate of Return
5. ROI: Return of Investiment
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Appendix C: Blood vessel decellularization reactor prototype
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